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Thyroid dysfunction syndromes (hypo and hyperthyroidism) have 
major impacts on the cardiovascular system. Whilst the short term 
effects of thyroid dysfunction on the cardiovascular system are 
clinically obvious and well studied, the long term effects and 
particularly the size of its effects on the cardiovascular system 
remain controversial.  
By combining the findings of the following studies with the review 
of literature that has been provided in the Introduction (Chapter 
1) and the ‘discussion’ sections of individual studies, the author 
concludes that the effects of thyroid dysfunction on the 
cardiovascular system are subtle, these effects do not always 
translate into adverse cardiovascular outcomes, and the magnitude 
of the effect is proportional to the severity of thyroid dysfunction.  
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This thesis has been organised in the following 6 chapters: 
Chapter 1: ‘Introduction’, is an overview of the current literature 
on the subject, summarising the short term and long term effects 
of hypo and hyperthyroidism on the cardiovascular system. An 
overview of other forms of thyroid disease has also been provided 
in this chapter. 
Chapter 2: ‘The effect of subclinical hypothyroidism on 
cardiovascular outcomes in type 2 diabetics’, for the first time 
looks at the relationship between subclinical hypothyroidism and 
cardiovascular outcomes in this high cardiovascular risk 
population and is currently under peer review for publication. 
Data analysis showed that there was no relationship between 
baseline or follow up serum TSH levels and cardiovascular 
mortality.  The unadjusted odds ratio (OR) was 1.27(95%CI=0.86, 
1.87, p =0.26).  Adjusting for age and sex did not alter the nature 
of this relationship: OR=1.17(95%CI=0.88, 1.56, p=0.27), and 
neither did further adjustment for the other baseline covariates 
(i.e. smoking, body mass index (BMI), diastolic and systolic blood 
pressures, HbA1c and lipids): OR=1.15 (95% CI= 0.58, 2.27, 
p=0.68). The data from this study suggest that subclinical 
hypothyroidism does not contribute to the excess risk of 
cardiovascular mortality in patients with type 2 diabetes, at least 5 
years after its diagnosis. 
Chapter 3: ‘The effect of thyroid dysfunction on N-terminal pro-
B-type natriuretic peptide concentrations’, examines the changes 
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in NT-pro-BNP in relation to hypo and hyperthyroidism. This 
study showed that treating hypothyroidism to euthyroid state is 
associated with a rise in NT-proBNP concentrations (p<0.001) 
and that treating hyperthyroidism leads to a fall; however, this 
trend towards lower NT-proBNP levels in hyperthyroid group 
after treatment hardly reached statistical significance (p=0.05). 
These changes seem to be secondary to a metabolic rate mediated 
effect on the peptide production. However, in the context of the 
high biological variation of NT-proBNP, the magnitude of these 
changes is likely to be of limited clinical relevance.   
Chapter 4: ‘The effect of thyroid dysfunction on peptide YY and 
Ghrelin’, examines the changes in these gut hormones in relation 
to hypo and hyperthyroidism. PYY and ghrelin have been shown 
to play important roles in body weight regulation. Changes in body 
weight are frequently seen with thyroid dysfunction. Obesity is a 
major cardiovascular risk factor. Data analysis showed that there 
was no significant change in PYY levels in either group before and 
after treatment (mean PYY in pmol/L±SD before and after 
treatment: 24.81±12.10 vs. 23.22±15.27, p=0.428 hypothyroid; 
19.47±8.09 vs. 20.87±10.26, p=0.464 hyperthyroid). The observed 
changes in ghrelin in both groups did not reach statistical 
significance either (mean ghrelin in pmol/L±SD before and after 
treatment: 761.32±435.46 vs. 697.60±376.09, p=0.227 
hypothyroid; p=0.058 for hyperthyroid group). This study showed 
that thyroid dysfunction does not alter plasma PYY and ghrelin 
concentrations and changes in weight associated with thyroid 
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dysfunction are more likely to be due to a combination of altered 
metabolic rate and the direct effect of T3 or lack of it on 
hypothalamus. 
Chapter 5: ‘The effect of dietary soy phytoestrogens on thyroid 
function and insulin resistance in patients with subclinical 
hypothyroidism: a double blind crossover study’, investigates the 
possible effect of soy phytoestrogens on thyroid function and 
cardiovascular risk markers. High content phytoestrogen soy 
supplement (16 mg phytoestrogen) is compared to a low content 
phytoestrogen supplement (2 mg phytoestrogen) – both 
containing equal amounts of soy protein – in a crossover design. 
The data from this study showed a significant reduction in systolic 
blood pressure of (mean ± SD) 2.57 ± 3.9 mmHg and diastolic 
blood pressure of (mean ± SD) 1.64 ± 3.7 mmHg after 16 mg 
phytoestrogen phase.  There was also a significant reduction of 
systolic blood pressure of (mean ± SD) 1.1 ± 3.9 mmHg after 
2mg phytoestrogen phase but no significant reduction in diastolic 
blood pressure. Other positive findings of the study were a 
significant improvement in insulin resistance measured by 
HOMA-IR (mean ± SD) [5.11 ± 12.2 vs. 4.2 ± 9.9 (p value= 0.02) 
95% CI 0.12, 1.63] and plasma glucose (mean ± SD) [5.6 ± 1.1 vs. 
5.3 ± 1.2 (p value= 0.006) 95% CI 0.11, 0.59] after 16mg 
phytoestrogen phase but not after 2mg phytoestrogen phase This 
study concludes that the cardiovascular protection suggested for 
phytoestrogens epidemiologically, may be through their positive 
effect on insulin resistance and blood pressure.  However, low and 
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high levels of dietary phytoestrogens have no clinical effect on 
thyroid function even in patients compromised with subclinical 
hypothyroidism.   
Chapter 6: ‘General discussion’, this final chapter provides a 
summary discussion, conclusion, the relevance of the work in this 
thesis in relation to the latest publications on the subject and scope 
for future work.  
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C h a p t e r  1  
INTRODUCTION 
The thyroid gland plays a pivotal role in tissue metabolism and 
development, and in doing so affects various organ systems. 
Whilst the effect of thyroid hormones on the cardiovascular 
system is of particular interest to this thesis, this chapter looks into 
the underlying causes and overall consequences of 
hyperthyroidism hypothyroidism and other forms of thyroid 
disease as well. 
1.1.History: The naming of the thyroid gland (Greek thyreos, 
shield, plus eidos, form) has been attributed to Wharton[1] in 1656 
(Figure 1.1), but an endocrine function was not proposed until 
almost 200 years later[2]. Appreciation of the clinical disorders 
affecting the thyroid followed, the earliest descriptions of which 
appeared in the following order: Thyroid cancer in 1811; diffuse 
toxic goitre by Parry in 1825, Graves in 1835, and von Basedow in 
1840; cretinism in 1871; myxoedema in 1874; thyroidectomy for 
the treatment of toxic goitre in 1884; thyroid extract therapy for 
myxoedema in 1891; Hashimoto disease in 1912; subacute (de 
Quervain) thyroiditis in 1936; the structure of thyroxine (T4) in 
1926; identification of triiodothyronine (T3) in 1952, the earliest 
evidence of the thyroid-stimulating antibodies of Graves’ disease 
in 1956; the presence of thyroid autoantibodies in Hashimoto’s 
disease in 1957; recognition of medullary thyroid carcinoma as a 
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distinct entity in 1959; and reports of cases of postpartum 
thyroiditis with hypothyroidism or thyrotoxicosis only since 1976 
to 1977[3].  
Other subsequent milestones included the first description of 
resistance to thyroid hormone in 1967; substantiation that 
circulating T3 was derived largely from peripheral 
monodeiodination of T4 in 1970; identification of T3-binding 
receptors in tissues in 1972 and their homology to the viral 
oncogene erbA in 1986; and demonstrations that point mutations 
in the thyroid-hormone receptor accounted for hormone 
resistance in 1989 and 1990. The thyrotropin (TSH) receptor was 
cloned in 1989; studies since have identified both loss of function 
and gain of function mutations in the TSH receptor that account 
for specific types of hypothyroidism and hyperthyroidism, 
respectively. The gene for the β subunit of TSH was then cloned, 
facilitating the development of human recombinant TSH 
(rhTSH)[3]; this agent has great clinical utility for the diagnosis and 
treatment of thyroid cancer and is used as an adjuvant treatment 
during cancer diagnostic protocols to detect recurring or 
remaining thyroid cancer cells in patients with a history of thyroid 
cancer as an alternative to thyroid hormone withdrawal[4]. 
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Figure 1.1 
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1.2.Anatomy and development: The location of the thyroid 
makes it readily accessible to both inspection and palpation. The 
normal adult thyroid gland consists of two lobes connected by an 
isthmus. Thyroid tissue is light brown, and the cut surface often 
glistens. The normal gland is surrounded by a delicate fibrous 
capsule and weighs 15 to 25 g. The normal thyroid is attached 
loosely to neighbouring structures, and the fascial planes are 
distinct (Figure 1.2). Four parathyroid glands, which produce 
parathyroid hormone, are located in the posterior region of each 
pole of the thyroid. The recurrent laryngeal nerves traverse the 
lateral borders of the thyroid gland and must be identified during 
thyroid surgery to avoid vocal cord paralysis. 
The thyroid gland develops from the floor of the primitive 
pharynx during the third week of gestation. The gland migrates 
from the foramen caecum, at the base of the tongue, along the 
thyroglossal duct to reach its final location in the neck. This 
feature accounts for the rare ectopic location of thyroid tissue at 
the base of the tongue (lingual thyroid), as well as for the presence 
of thyroglossal duct cysts along this developmental tract. Thyroid 
hormone synthesis normally begins at about 11th week of 
gestation. 
The mature thyroid gland contains numerous follicles composed 
of thyroid follicular cells that surround secreted colloid, a 
proteinaceous fluid that contains large amounts of thyroglobulin, 
the protein precursor of thyroid hormones[5].  
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Figure 1.2 The thyroid gland (adapted from Thibodeau / Patton’s: The 
Human Body in Health and Disease, 3rd edition, 2002) 
1.3.Regulation of the thyroid axis: Thyroid stimulating 
hormone (TSH) secreted by the thyrotrope cells of the anterior 
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pituitary, plays a pivotal role in the control of the thyroid axis and 
serves as the most useful physiologic marker of thyroid hormone 
action. TSH is a 31-kDa hormone composed of α and β subunits; 
the α subunit is common to the other glycoprotein hormones 
(luteinizing hormone, follicle-stimulating hormone, human 
chorionic gonadotropin (hCG)), whereas the TSH β subunit is 
unique to TSH. The extent and nature of carbohydrate 
modification are modulated by thyrotropin-releasing hormone 
(TRH) stimulation and influence the biologic activity of the 
hormone. The thyroid axis is a classic example of an endocrine 
feedback loop. Hypothalamic TRH stimulates pituitary production 
of TSH, which, in turn, stimulates thyroid hormone synthesis and 
secretion. Thyroid hormones feed back negatively to inhibit TRH 
and TSH production (Figure 1.3). The "set-point" in this axis is 
established by TSH, the level of which is a sensitive and specific 
marker of thyroid function. TRH is the major positive regulator of 
TSH synthesis and secretion. TRH acts through a seven-
transmembrane G protein-coupled receptor (GPCR) that activates 
phospholipase C to generate phosphatidylinositol turnover and the 
release of intracellular calcium. Peak TSH secretion occurs ~15 
min after administration of exogenous TRH. Dopamine, 
glucocorticoids, and somatostatin suppress TSH but are not of 
major physiologic importance except when these agents are 
administered in pharmacologic doses. Like other pituitary 
hormones, TSH is released in a pulsatile manner and exhibits a 
diurnal rhythm; its highest levels occur at night. However, these 
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TSH excursions are modest in comparison to those of other 
pituitary hormones, in part because TSH has a relatively long 
plasma half-life (50 min). Consequently, single measurements of 
TSH are adequate for assessing its circulating level[5].  
 
 
 
Figure 1.3: Regulation of thyroid hormone synthesis (adapted from Harrison’s 
Principles of Internal Medicine, 15th edition, 2001) 
1.4.Thyroid hormone synthesis: The major synthetic steps 
regulated by TSH are transport of iodide, organification, coupling, 
thyroglobulin (Tg) synthesis, and endocytotic secretion. Under the 
stimulation of TSH, the thyroid cells remove iodide from the 
capillary network at the base of the cell and move the iodide to the 
apex of the cell, where it is joined with molecules of tyrosine to 
make mostly T4 and some T3. T4 and T3 are stored in colloid 
within the follicles of the gland. They are then released together, 
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or some T4 is further deiodinated to T3 before release. These two 
steps are also under the influence of TSH or other proteins that 
bind to the TSH receptor. Mutations of this TSH receptor are 
continuously activated in some toxic adenomas and multinodular 
goitres[6]. A small but measurable amount of non-TSH-dependent 
T4 secretion also occurs normally[3]. The tyrosine residues to 
which the iodine is joined in the organification process are part of 
the Tg molecule, a 660-kDa glycoprotein. Defects in Tg synthesis 
have been proposed to cause some cases of goitre, although such 
cases are rare. Serum values of Tg are extremely useful in the 
management of well-differentiated thyroid cancer as an indicator 
of biologic activity or recurrence[7]. Figure 1.4 summarises the 
stages in thyroid hormone synthesis. 
1.5.Thyroid hormone transport and metabolism: T4 is secreted 
from the thyroid gland in at least 20-fold excess over T3. Both 
hormones circulate bound to plasma proteins, including thyroxine-
binding globulin (TBG), transthyretin (TTR, formerly known as 
thyroxine-binding prealbumin, or TBPA), and albumin. The 
functions of serum-binding proteins are to increase the pool of 
circulating hormone, delay hormone clearance, and perhaps to 
modulate hormone delivery to selected tissue sites. The 
concentration of TBG is relatively low (1 to 2 mg/dL), but 
because of its high affinity for thyroid hormones (T4 > T3), it 
carries about 80% of the bound hormones. Albumin has relatively 
low affinity for thyroid hormones but has a high plasma 
concentration and it binds up to 10% of T4 and 30% of T3. TTR 
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also carries about 10% of T4 but little T3[5]. Only the free 
hormone is biologically available to tissues. Therefore, 
 
Figure1.4: Thyroid hormone synthesis.  
Iodide (I-) is transported by the iodide transporter (IT) from the plasma into 
the thyroid cell and then I– moves to the apical membrane, where it is 
organified and coupled under the influence of thyroid peroxidase (TPO) to 
thyroglobulin (Tg), which is synthesized within the cell. Hormone stored as 
colloid reenters the cell through endocytosis and moves back toward the basal 
membrane, where T4 and T3 are secreted. Nonhormonal iodide is recycled. 
Hormone synthesis may be inhibited at: (1) iodine transport by thiocyanate, 
perchlorate, interleukin-1, and tumour necrosis factor-α; (2) organification and 
(3) coupling by propylthiouracil (PTU) and carbiimazole and through 
decreasing TPO by interferon-γ and interleukin-1; (4) endocytosis by lithium 
and iodide; (5) thyroglobulin proteolysis by iodide; and (6) intrathyroidal 
deiodination by PTU and tumour necrosis factor-α (adapted from Becker’s 
Principles and Practice of Endocrinology and Metabolism, 3rd edition, 2002). 
 
homeostatic mechanisms that regulate the thyroid axis are directed 
towards maintenance of normal concentrations of free hormones. 
About 80% of T4 is metabolised by deiodination, 35% to T3 and 
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45% to reverse T3 (rT3). The remainder is inactivated mostly by 
glucuronidation in the liver and secretion into bile, or to a lesser 
extent by sulfonation and deiodination in the liver or kidney. 
Other metabolic reactions include deamination of the alanine side 
chain, forming thyroacetic acid derivatives of low biologic activity; 
or decarboxilation or cleavage of the ether bridge, forming inactive 
compounds[8]. 
1.6.Thyroid hormone action: Thyroid hormones act by binding 
to nuclear receptors, called thyroid hormone receptors (TRs) α 
and β. Both TRα and TRβ are expressed in most tissues, but their 
relative levels of expression vary among organs; TRα is particularly 
abundant in brain, kidney, gonads, muscle, and heart, whereas 
TRβ expression is relatively high in the pituitary and liver. Both 
receptors are variably spliced to form unique isoforms. The TRβ2 
isoform, which has a unique amino terminus, is selectively 
expressed in the hypothalamus and pituitary, where it appears to 
play a role in feedback control of the thyroid axis. The TRα2 
isoform contains a unique carboxy terminus that prevents thyroid 
hormone binding; it may function to block the action of other TR 
isoforms. 
The TRs contain a central DNA-binding domain and a C-terminal 
ligand-binding domain. They bind to specific DNA sequences, 
termed thyroid response elements (TREs), in the promoter 
regions of target genes (Figure 1.5). The activated receptor can 
either stimulate gene transcription (e.g., myosin heavy chain α) or 
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inhibit transcription (e.g., TSH β-subunit gene), depending on the 
nature of the regulatory elements in the target gene.  
 
Figure 1.5: Mechanism of thyroid hormone receptor action (adapted from 
Harrison’s Principles of Internal Medicine, 15th edition, 2001) 
Thyroid hormones bind with similar affinities to TRα and TRβ. 
However, T3 is bound to its receptors with about 10 to 15 times 
greater affinity than T4, which explains its increased hormonal 
potency. Though T4 is produced in excess of T3, receptors are 
occupied mainly by T3, reflecting T4 to T3 conversion by 
peripheral tissues, greater T3 bioavailability in the plasma, and 
receptors' greater affinity for T3. After binding to TRs, thyroid 
hormone induces conformational changes in the receptors that 
modify its interactions with accessory transcription factors. In the 
absence of thyroid hormone binding, the aporeceptors bind to 
corepressor proteins that inhibit gene transcription. Hormone 
binding dissociates the corepressors and allows the recruitment of 
coactivators that enhance transcription. The discovery of TR 
interactions with corepressors explains the fact that TR silences 
gene expression in the absence of hormone binding. 
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Consequently, hormone deficiency has a profound effect on gene 
expression because it causes active gene repression as well as loss 
of hormone-induced stimulation. This concept has been 
corroborated by the finding that targeted deletion of the TR genes 
in mice has a less pronounced phenotypic effect than hormone 
deficiency[5]. 
1.7.Thyroid autoimmunity and its genetics: Autoimmune 
thyroid disease (AITD) comprises a series of interrelated 
conditions including Graves’ disease (GD), Hashimoto’s 
thyroiditis (HT), atrophic autoimmune hypothyroidism, 
postpartum thyroiditis (PPT), and thyroid eye disease. These 
different manifestations of AITD may coincide, most frequently 
as the combination of GD and thyroid eye disease. Together, 
AITDs are the commonest autoimmune disorders in the 
population, affecting between 2% and 4% of women and up to 
1% of men[9, 10]. Furthermore, AITD prevalence increases with 
advancing age, with more than 10% of subjects over 75 yr of age 
having biochemical evidence of mild (subclinical) hypothyroidism, 
the majority of which is due to autoimmune disease[10, 11]. 
A multifactorial model has widely been accepted to explain the 
aetiological basis of AITD, indicating a background inherited 
predisposition to autoimmunity, with additional environmental 
and hormonal factors that trigger or contribute to the 
development of disease. This model has been substantiated by 
familial clustering and twin studies clearly demonstrating that 
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AITD does not occur because of a single gene defect and does not 
follow a simple pattern of Mendelian inheritance[12-14]. There is 
also good evidence that both cigarette smoking and psychosocial 
stress are associated with the development of GD[15-17]. 
Similarly, the female preponderance of human AITDs[9], the 
modulation of animal models of AITD with gonadal steroids[18], 
the amelioration of GD during pregnancy, and the occurrence of 
PPT all support the important role of sex steroids in these 
disorders[19]. Further supporting the role of environmental 
factors in AITD, a recently published study comparing two 
neighbouring populations of Karelian Russians and Finish 
schoolchildren even suggested that inferior prosperity and 
standard of hygiene may provide protection against thyroid 
autoimmunity[20].  In an attempt to quantify the contribution of 
genetic versus environmental factors in the pathogenesis of GD, 
Brix et al demonstrated that the concordance rate for AITD 
among monozygotic twins was in the range of 35–55% compared 
with 3% in dizygotic twins. The same group showed that 79% of 
the likelihood of developing GD was attributable to genetic 
factors; and that individual specific environmental factors not 
shared by the twins accounted for the remaining 21%[21]. 
Therefore it seems that clarifying the genetic basis of AITD is 
pivotal to its understanding. 
The genetic predisposition to AITD is determined by a series of 
interacting susceptibility alleles of several different genes. These 
various genetic loci may also have differing influences on the 
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predisposition to AITD in different populations (locus 
heterogeneity), which makes the identification of disease 
susceptibility genes more difficult. Of the candidate genes studied 
so far, four loci deserve specific attention. The first two, the 
human leukocyte antigen (HLA) gene region and cytotoxic T 
lymphocyte antigen 4 (CTLA4) have stood the test of time and 
most researchers have found convincing evidence of their 
association with AITD. The other two candidate genes, i.e. the 
thyroglobulin gene and CD40 have attracted significant interest in 
recent years following family-based linkage data. Whilst some 
replication has been reported, on balance, these regions have 
generated conflicting data with true confirmation still awaited[22]. 
The major histocompatibility complex (MHC), which contains the 
HLA genes, is located on chromosome 6p21. It is subdivided into 
three regions: 1) the class I region, which encodes HLA antigens 
A, B, and C; 2) the class II region, which encodes HLA antigens 
DR, DQ, and DP, each with one or more α and ß chains; and 3) 
the class III region, encoding several immunoregulatory molecules 
including complement components, heat shock protein 70 
(HSP70), and TNF. The class II region also contains the peptide 
transporters associated with antigen processing (TAP) and large 
multifunctional protease (LMP) genes. Tight linkage 
disequilibrium (i.e. conserved haplotypes) exists between the alleles 
of the MHC region. The MHC class II molecules play a critical 
part in the initiation of adaptive immune responses. Peptide 
antigens can only be recognized by T cell receptors when they are 
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attached to the binding groove of an MHC molecule on the 
surface of an antigen-presenting cell. This, together with the 
presence of several other immunoregulatory genes in the region, 
makes the MHC a strong candidate locus for AITD and other 
autoimmune diseases[19].  
The association between GD and the alleles of MHC class I, with 
a higher frequency of HLA-B8 in GD patients was first shown by 
Grumet et al in 1974[23]; and was later confirmed by several other 
studies[24-26]. However, a stronger association of GD was found 
with the MHC class II allele, HLA-DR3, which is in strong linkage 
disequilibrium with HLA-B8[27]. Many case-control studies in 
white populations have since consistently shown the association of 
GD with HLA-DR3, with relative risks between 2.5 and 5[19]. 
Heward et al showed that linkage disequilibrium between GD and 
the HLA class II region is due to the extended haplotype 
DRB1*0304-DQB1*02-DQA1*0501[28]. Although there is now 
little doubt about the association of GD with the HLA DR3-
carrying haplotype in whites, the primary disease susceptibility 
allele in the region remains unknown. Yanagawa et al have 
reported an association of GD, particularly in males, with the 
HLA-DQA1*0501 allele, which was stronger than, and 
independent of, the HLA DR3 status[29, 30]. This independent 
association of HLA-DQA1*0501 with GD has been supported by 
some studies, but not by others[19]. The phenomenon of linkage 
disequilibrium is, however, extremely strong across the whole 
HLA region making it difficult to determine the exact location(s) 
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of aetiological DNA variants detected. This has lead to the 
suggestion that the HLA region could harbour additional 
susceptibility loci within either the HLA class II region or the 
surrounding class I or class III regions. Work within the HLA 
region is ongoing to determine the exact location(s) of additional 
aetiological variants within[22]. 
Data on HLA haplotypes in Hashimoto’s thyroiditis (HT) have 
been less definitive than in GD. A general methodological 
problem has been disease definition. Although the diagnosis of 
GD may be relatively straightforward, the definition of HT has 
been more controversial. HT encompasses a spectrum of 
manifestations, ranging from the simple presence of thyroid 
autoantibodies with focal lymphocytic infiltration, which may be 
of no functional consequence (asymptomatic autoimmune 
thyroiditis), to the presence of goitrous or atrophic thyroiditis, 
characterized by gross thyroid failure[31]. Initial studies failed to 
demonstrate an association between goitrous HT and HLA A-, B-, 
or C-antigens. Later studies showed an association of goitrous HT 
with HLA DR5 (RR, 3.1) and of atrophic HT with DR3 (RR, 
5.1)[32]. 
CTLA4 is an immunoregulatory molecule that is expressed on the 
surface of activated T lymphocytes. The suppressive effects of 
CTLA-4 on T cell activation have raised the possibility that 
mutations altering CTLA-4 expression and/or function could 
result in an exaggerated T cell activation and lead to the 
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development of autoimmunity[32]. In the human, the CTLA4 
gene is located on chromosome 2q33. CTLA4 polymorphisms 
have been extensively studied for linkage and association in 
various autoimmune disorders. It has been suggested that the 
CTLA4(AT)n polymorphism, for instance, may be functionally 
important because larger-sized alleles of this polymorphism may 
adversely affect the stability of the mRNA transcript[33]. 
Following a large re-sequencing effort and fine mapping of all 
common variants within the gene, disease susceptibility was finally 
mapped to four single nucleotide polymorphisms (SNP) (CT60, 
J030, JO31 and JO27–1) within a noncoding 6·1 kb region, with 
the common allelic variation of the CT60 SNP associated with 
lower messenger RNA levels of the soluble alternative splice form 
of CTLA[34]. Association of the CT60 SNP has been confirmed 
by several independent studies and most recently was shown to be 
highly associated with GD in a meta-analysis using data collected 
from 7246 GD patients[35] and similar associations have been 
reported for HT[34]. The mechanism by which polymorphism of 
CTLA4 acts to inhibit autoimmunity and specifically the role of 
soluble, as opposed to full length CTLA4, currently remains 
unknown, but is the subject of ongoing research. Whilst the 
noncoding 6·1 kb region described above almost certainly 
harbours an aetiological DNA variant, it is still possible that there 
are other polymorphisms within the region attributing to 
AITD[22]. 
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Looking back at the evolution of AITD genetics over the past 4 
decades shows that it has been a slow but steady and progressive 
process. The most recent step in the evolution of genetic studies 
of common autoimmune diseases - including AITD - sees 
association analysis performed at a genome-wide level to produce 
genome-wide association studies. These studies bring together the 
latest advances in our genetic maps, large scale automated 
genotyping technologies and large national DNA collections[22]. 
In the UK the Wellcome Trust Case Control Consortium has 
conducted a large association study involving four disease states 
including AITD in which over 15000 nonsynonymous coding 
SNPs are being typed in 1000 cases and 1000 controls[36]. Whilst 
this study has produced data directly related to AITD, it is also 
important to examine data from another larger study conducted by 
Wellcome Trust[37] which includes, for example, type 1 diabetes 
and rheumatoid arthritis to determine whether any novel loci 
identified in these two diseases are acting as common 
autoimmunity loci and predisposing to AITD. New discoveries are 
also influencing the next phase in AITD genetics. The recent 
discovery of copy number variation (CNV) within the genome 
which influences gene expression, phenotypic variation and gene 
dosage are also believed to play a key role in disease susceptibility 
and await further investigation[38]. The study of epigenetics, 
concerned with the ‘switching off ’ of genes, is also starting to a 
greater extent in GD with most of the work to date mainly 
focused on X chromosome inactivation and the effect that this 
  19 
may have in explaining the AITD high female prevalence[22]. The 
study of AITD genetic susceptibility is an intriguing area with 
major potentials for producing novel therapeutic targets and 
treatments. 
1.8.Hyperthyroidism: 
Hyperthyroidism is the result of excess synthesis and release of 
thyroid hormone. Thyrotoxicosis is the hypermetabolic state 
associated with elevated levels of free thyroxine (fT4), free 
triiodothyronine (fT3), or both.  
1.8.1.Causes of hyperthyroidism: The most common forms of 
hyperthyroidism include diffuse toxic goitre (Graves’ disease), 
toxic multinodular goitre (Plummer’s disease), and toxic adenoma. 
Together with subacute thyroiditis, these conditions constitute 85-
90% of all causes of thyrotoxicosis.  
The most common cause of thyrotoxicosis is Graves’ disease (50-
60%). Graves’ disease is an organ-specific autoimmune disorder 
characterized by a variety of circulating antibodies, including 
common autoimmune antibodies, antithyroperoxidase (anti-TPO), 
and antithyroglobulin (anti-Tg) antibodies. The most specific 
autoantibody is thyroid-stimulating immunoglobulin (TSI). TSI is 
directed toward epitopes of the thyroid-stimulating hormone 
(TSH) receptor and acts as a TSH-receptor agonist. 
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Table 1.8.1 Common, less common and uncommon forms of 
thyrotoxicosis and hyperthyroidism 
Common Forms (85-90% of cases) Radioactive iodine 
uptake over neck 
Diffuse toxic goitre (Graves’ disease) Increased 
Toxic multinodular goitre (Plummer’s disease) Increased 
Thyrotoxic phase of subacute thyroiditis Decreased 
Toxic adenoma Increased 
Less Common Forms 
Iodide-induced thyrotoxicosis Variable 
Thyrotoxicosis factitia Decreased 
Uncommon Forms 
Pituitary tumours producing thyroid-stimulating 
hormone 
Increased 
Excess human chorionic gonadotropin (molar 
pregnancy/choriocarcinoma) 
Decreased 
Pituitary resistance to thyroid hormone Increased 
Metastatic thyroid carcinoma Decreased 
Struma ovarii with thyrotoxicosis Decreased 
Similar to TSH, TSI binds to the TSH receptor on the thyroid 
follicular cells to activate thyroid hormone synthesis and release 
and thyroid hypertrophy. This results in the characteristic picture 
of Graves’ thyrotoxicosis, with a diffusely enlarged thyroid, very 
high radioactive iodine uptake, and excessive thyroid hormone 
levels compared to a healthy thyroid. Thyroid hormone levels can 
be extremely elevated in this condition. Clinical findings specific 
to Graves’ disease include thyroid ophthalmopathy (periorbital 
oedema, chemosis [conjunctival oedema], injection, and 
proptosis) and, rarely, dermopathy over the lower extremities. 
This autoimmune condition may be associated with other 
autoimmune diseases such as pernicious anaemia, myasthenia 
gravis, vitiligo, adrenal insufficiency, and type 1 diabetes mellitus. 
  21 
The next most common cause of thyrotoxicosis, subacute 
thyroiditis, comprising approximately 15-20% of cases of 
hyperthyroidism, is discussed under 1.11. 
Toxic multinodular goitre (Plummer’s disease) occurs in 15-20% 
of patients with thyrotoxicosis. It occurs more commonly in 
elderly individuals, especially in patients with a long-standing 
goitre. Thyroid hormone excess develops very slowly over time 
and often is only mildly elevated at the time of diagnosis. As 
discussed below, very high thyroid hormone levels may occur in 
this condition after high iodine intake, i.e., with contrast or 
amiodarone exposure. Symptoms of thyrotoxicosis are mild, often 
because only a slight elevation of thyroid hormone levels is 
present, and the signs and symptoms of thyrotoxicosis often are 
blunted (apathetic hyperthyroidism) in older patients. A typical 
nuclear scintigraphy scan of a toxic multinodular goitre 
demonstrates an enlarged thyroid gland with areas of increased 
and decreased activity. 
Toxic adenoma is caused by a single hyperfunctioning follicular 
thyroid adenoma. Patients with a toxic thyroid adenoma 
comprise approximately 3-5% of patients who are thyrotoxic. 
The excess secretion of thyroid hormone occurs from a benign 
monoclonal tumour that usually is larger than 2.5 cm in diameter. 
The excess thyroid hormone suppresses TSH levels. Radioactive 
iodine uptake is usually normal, and the radioactive iodine scan 
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shows only the hot nodule, with the remainder of the normal 
thyroid gland suppressed because the TSH level is low. 
Several rare causes of thyrotoxicosis exist that deserve mention. 
Iodide-induced thyrotoxicosis (Jod-Basedow syndrome) occurs in 
patients with excessive iodine intake, such as after an iodinated 
radiocontrast study. It occurs in patients with areas of thyroid 
autonomy such as a multinodular goitre or autonomous nodule. 
The thyrotoxicosis appears to be a result of loss of the normal 
adaptation of the thyroid to iodide excess. It is treated by 
cessation of the excess iodine intake and administration of 
antithyroid medication. Usually, after depletion of the excess 
iodine, thyroid functions return to preexposure levels. Euthyroid 
patients previously treated with antithyroid drugs for Graves' 
disease are also prone to develop iodine-induced 
hyperthyroidism[39]. Evidence that iodine can act as an immune 
stimulator exists, precipitating autoimmune thyroid disease and 
acting as a substrate for additional thyroid hormone synthesis[40]. 
Struma ovarii is ectopic thyroid tissue associated with dermoid 
tumours or ovarian teratomas that can secrete excessive amounts 
of thyroid hormone and produce thyrotoxicosis. 
Patients with a molar hydatidiform pregnancy or 
choriocarcinoma have extremely high levels of beta human 
chorionic gonadotropin (βHCG) that can weakly activate the 
TSH receptor. At very high levels of βHCG, activation of the 
TSH receptor occurs that is sufficient to cause thyrotoxicosis. 
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Physiological maximum elevation of βHCG at the end of the first 
trimester of pregnancy is associated with a mirror-image 
temporary reduction in TSH. Despite the reduction in TSH, the 
free T4 (fT4) levels usually remain normal or only slightly above 
the reference range. As the pregnancy progresses and the βHCG 
plateaus at a lower level, TSH levels decrease back to normal 
levels. 
1.8.2.Clinical manifestations of hyperthyroidism: Nonspecific 
changes due to excessive thyroid hormone include weight loss, 
nervousness, fatigue, heat intolerance, and rapid heartbeat or 
palpitations sometimes associated with atrial fibrillation and high-
output congestive heart failure (CHF). An increase in the rate of 
bone resorption occurs and it has been shown that overt 
symptomatic hyperthyroidism is associated with decreased BMD 
during the first 3 years after diagnosis and treatment of the 
disease. This effect is reversible with appropriate treatment after 
this period of time[41]. Thyroid hormone excess causes left 
ventricular thickening, which is associated with an increased risk 
of CHF. Thyrotoxicosis has been associated with dilated 
cardiomyopathy, right heart failure with pulmonary hypertension, 
and diastolic dysfunction (discussed in more detail under 1.14.1). 
Ophthalmopathy and dermopathy specifically associated with 
Graves’ disease include periorbital oedema, chemosis, and 
proptosis with extraocular muscle dysfunction and diplopia. 
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The presentation of thyrotoxicosis is variable among patients. 
Younger patients tend to exhibit symptoms of more sympathetic 
activation, such as anxiety, hyperactivity, and tremor, while older 
patients have more cardiovascular symptoms, including dyspnoea 
and atrial fibrillation with weight loss. The clinical manifestations 
of thyrotoxicosis do not always correlate with the extent of the 
biochemical abnormality. 
1.8.3.Laboratory measurements: The most reliable screening 
measure of thyroid function is a TSH level. TSH levels usually 
are suppressed to immeasurable levels (<0.05 mU/L) in 
thyrotoxicosis. To estimate the degree of thyrotoxicosis, TSH 
measurement should be combined with serum levels of free T4 
(and T3 if T4 levels are normal). Of patients with thyrotoxicosis, 
5% have only elevated T3 levels. 
The most specific autoantibody for autoimmune thyroiditis is an 
enzyme-linked immunosorbent assay (ELISA) for anti-TPO 
antibody (thyroperoxidase). The titres usually are significantly 
elevated in the most common type of hyperthyroidism, Graves’ 
thyrotoxicosis, and usually are low or absent in toxic 
multinodular goitre and toxic adenoma. A significant number of 
healthy people without active thyroid disease have mildly positive 
TPO antibodies, thus the test should not be performed for 
screening purposes. TSI, if elevated, helps establish the diagnosis 
of Graves’ disease. A positive antithyroglobulin antibody test 
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does not predict the development of thyroid dysfunction and 
should not be measured. 
1.8.4.Imaging studies: If the aetiology is not clear after physical 
examination and other laboratory tests, the aetiology of 
thyrotoxicosis can be confirmed by nuclear thyroid scintigraphy 
iodine 123 (123I) uptake and scan. Values are elevated in patients 
with Graves’ disease and toxic multinodular goitres. Both 123I and 
technetium-99m can be used for thyroid scanning, which 
provides anatomic information on the type of goitre (e.g., diffuse 
vs. nodular). Scans essentially are pictures of the thyroid and do 
not necessarily confirm or refute the presence of 
hyperthyroidism per se; only 123I uptake provides information in 
this area. If a dominant nodule is found upon examination of a 
patient with thyrotoxicosis, an 123I thyroid scan is recommended 
to assure that the dominant nodule is functioning. If the nodule 
is cold, a biopsy on the nodule by fine-needle aspiration to 
exclude concomitant malignancy is warranted. 
1.8.5.Treatment: With the exception of low 123I uptake 
hyperthyroidism (e.g., subacute thyroiditis), the treatment of 
hyperthyroidism includes symptomatic relief and treatment with 
antithyroid medications, radioactive iodine (131I), or thyroidectomy. 
Symptomatic relief from the neurological and cardiovascular 
symptoms of thyrotoxicosis is normally achieved by beta-blocker 
therapy. Calcium channel blockers can be used for the same 
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purposes when beta-blockers are contraindicated or poorly 
tolerated. 
Antithyroid drugs (e.g., carbimazole, propylthiouracil) have been 
used for hyperthyroidism since their introduction in the 1940s. 
These drugs inhibit multiple steps in the synthesis of T4 and T3, 
leading to a gradual reduction in thyroid hormone levels over 2-8 
weeks or longer. Dose titration should be made every 4 weeks 
until thyroid functions normalize. Some patients with Graves’ 
disease go into a remission after treatment for 12-18 months, and 
the drug can be discontinued. Notably, half the patients who go 
into remission have another recurrence of hyperthyroidism within 
the following year. Nodular forms of hyperthyroidism (toxic 
multinodular goitre and toxic adenoma) are permanent conditions 
and will not go into remission. Antithyroid medications inhibit 
formation and coupling of iodotyrosines in thyroglobulin, which 
are necessary for thyroid hormone synthesis. A second therapeutic 
action of propylthiouracil, but not carbimazole, is the inhibition of 
conversion of T4 to T3. A quick reduction in T3 is theoretically 
associated with a clinically significant improvement in thyrotoxic 
symptoms. The choice between propylthiouracil and carbimazole 
is somewhat arbitrary. Carbimazole is a more potent and longer-
acting drug. Often, patient compliance is better with carbimazole 
taken once or twice daily than with propylthiouracil given 3 or 4 
times daily. Propylthiouracil often is the drug of choice in severe 
thyrotoxicosis because of the additional benefit of inhibition of 
peripheral T4 to T3 conversion. 
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The most common side-effects of antithyroids are allergic 
reactions of fever, rash, urticaria, and arthralgia, which occur in 1-
5% of patients usually within the first few weeks of treatment. 
Serious adverse effects include agranulocytosis, aplastic anaemia, 
hepatitis, polyarthritis, and a lupuslike vasculitis. All of these 
adverse effects, except agranulocytosis, occur more frequently 
with propylthiouracil. Agranulocytosis occurs in 0.2-0.5% of 
patients, with an equal frequency for both drugs. Patients with 
agranulocytosis usually present with fever and pharyngitis. After 
the drug is stopped, granulocyte counts usually start to rise within 
several days but may not normalize for 10-14 days. Granulocyte 
colony-stimulating factor (G-CSF) appears to accelerate recovery 
in patients with mild to moderate but not severe agranulocytosis 
[42]. Interestingly, significantly elevated serum G-CSF levels were 
observed in patients with Graves' hyperthyroidism and deficiency 
of G-CSF as a result of antithyroid therapy (methimazole) was not 
identified as a cause of agranulocytosis in one study[43]. 
In severe thyrotoxicosis from Graves’ disease or subacute 
thyroiditis, iodine or iodinated contrast agents have been 
administered to block T4 conversion to T3 and the release of 
thyroid hormone from the gland. This therapy is reserved for 
severe thyrotoxicosis because its use prevents definitive therapy of 
Graves’ thyrotoxicosis with radioactive iodine for many weeks. 
Either a saturated solution of potassium iodide or iopanoic 
acid/ipodate or Lugol’s solution can be administered with rapid 
reduction in T3 levels. Care should be taken not to administer 
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these drugs to patients with toxic multinodular goitre or toxic 
adenomas. The autonomous nature of these conditions can lead to 
worsening of the thyrotoxicosis in the presence of 
pharmacological levels of iodide, a substrate for thyroid hormone 
synthesis. 
Radioactive iodine (131I) has been used to treat Graves’ disease 
since the 1940s, and its use has enjoyed increasing popularity 
because of its efficacy, few side effects and cost effectiveness[44]. 
Although the effect is less rapid than antithyroid medication or 
thyroidectomy, it is effective, safe, and does not require 
hospitalisation. It is administered orally as a single dose, in capsule 
or liquid form. The radioactive iodine is quickly absorbed and 
taken up by the thyroid. No other tissue or organ in the body is 
capable of retaining the radioactive iodine and, therefore, very few 
adverse effects are associated with this therapy. The treatment 
results in a thyroid-specific inflammatory response, causing 
fibrosis and destruction of the thyroid over weeks to many 
months. Hypothyroidism is an expected and even desirable result 
of 131I treatment. After radiotherapy, patients are counselled not to 
have close contact with family members for ~7 days and, because 
of salivary radioiodine, should not share eating or drinking 
utensils. Particular care should be exercised if there is a pregnant 
woman or a child in the household. An increase in cardiovascular 
and cerebrovascular mortality has been reported in a number of 
studies[45-47]. However, the findings suggest that it is 
hyperthyroidism itself which was the major factor determining 
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adverse outcome. This is probably mediated through influences of 
cardiac rate, rhythm and function, as well as exacerbation of any 
underlying valvular, hypertensive or ischaemic heart disease[48]. 
Although several studies of cancer risk in patients treated with 131I 
for hyperthyroidism have been reported, results have been 
conflicting. The evidence does suggest an increased relative risk of 
thyroid cancer in hyperthyroid patients treated with radioiodine, 
although the absolute risk remains small, and indeed is likely to 
reflect, at least in part, association with underlying thyroid disease 
rather than 131I exposure per se[48]. Follow-up studies have not 
associated 131I therapy with a higher risk of carcinoma in general, 
and leukaemia or lymphoma in particular[49]. 
Thyroidectomy: Total thyroidectomy, subtotal thyroidectomy and 
combinations of hemithyroidectomies with contralateral subtotal 
thyroidectomies have been used for the treatment of 
hyperthyroidism. Of these, total thyroidectomy appears to be the 
preferred mode of treatment as it guarantees cure, and, although it 
also guarantees hypothyroidism, thyroxine replacement treatment 
is far more predictable as the operation is clearly defined, as 
opposed to subtotal thyroidectomy where the amount of thyroid 
tissue left behind varies from centre to centre. Also, subtotal 
thyroidectomy is associated with a high rate of hypothyroidism 
and remnants of the thyroid gland have potential for recurrence. 
Total thyroidectomy obviates these disadvantages and can be 
performed without increased complication rates[50, 51]. 
Thyroidectomy may be of particular benefit to those who require 
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normalisation of thyroid functions quickly, such as pregnant 
women, women who desire pregnancy in the next 6 months, or 
patients with unstable cardiac conditions; patients with very large 
goitres or severe ophthalmopathy; patients who refuse radioactive 
iodine therapy; those with refractory amiodarone-induced 
hyperthyroidism and children with severe hyperthyroidism. 
Preoperative preparation includes antithyroid medication, stable 
(cold) iodine treatment (to decrease gland vascularity), and beta-
blocker therapy. Adverse effects of therapy include recurrent 
laryngeal nerve damage and hypoparathyroidism due to damage of 
local structures during surgery. No significant difference in the 
complication rate exists between subtotal and total 
thyroidectomy[52]. 
1.8.6.Complications:  
Graves’ Ophthalmopathy: Graves’ ophthalmopathy is more common 
in women than in men. Although 50% of patients with Graves’ 
disease have clinical evidence of thyroid eye disease, only 5% 
develop severe ophthalmopathy, e.g., diplopia, visual-field deficits, 
blurred vision, tearing, and photophobia. Management of Graves' 
ophthalmopathy is preferably done in a multidisciplinary setting. 
Smoking is associated with worse disease outcome. Arguably, 131I 
therapy for hyperthyroidism can also worsen ophthalmopathy, 
especially if administered during active disease or to patients who 
smoke or have severe hyperthyroidism, or those with high levels 
of TSH-receptor-binding inhibitory immunoglobulins. 
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Coadministration of steroids and 131I therapy is recommended for 
such high-risk patients. 131I therapy is safe for patients with 
inactive Graves' ophthalmopathy. Subtotal thyroidectomy and 
antithyroid drugs show no benefit or harm to eye changes. There 
is no good evidence that total thyroid ablation has additional 
benefit. Artificial teardrops, dark glasses and prisms are very 
helpful. Dysthyroid optic neuropathy is best treated with 
intravenous pulsed methylprednisolone; if visual functions do not 
recover, urgent surgical decompression is indicated. A wait-and-
see policy is recommended in mild Graves' ophthalmopathy 
because the natural history of this condition reveals a tendency to 
resolve spontaneously. Active, moderately severe Graves' 
ophthalmopathy qualifies for immunosuppression; intravenous 
pulsed methylprednisolone is more efficacious and has fewer side 
effects than oral steroids. Once the disease is inactive, 
rehabilitative surgery has much to offer. Quality of life is seriously 
limited in patients with Graves' ophthalmopathy, and remains 
restricted even after all treatments. Consequently, there is an 
urgent need for improved treatment modalities, and antibody 
therapy has shown promise in this respect[53]. 
Graves’ Dermopathy: This is an infiltrative dermopathy, usually over the 
lower extremities, that is characterized by an accumulation of 
glycosaminoglycans and inflammatory cells in the dermis. The skin 
changes usually include a nonpitting erythematous oedema of the 
anterior shins. Dermopathy and acropachy appear to be markers 
of severe ophthalmopathy. Occasionally, however, Graves' 
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dermopathy occurs without clinical ophthalmopathy[54]. No 
effective treatment exists. Nightly occlusive wraps of the affected 
site are recommended with plastic wrap after application of a high-
potency topical steroid cream. 
Osteoporosis:  Osteoporosis is characterised by low bone mass, 
deterioration of bone microarchitecture, increased bone fragility, 
and susceptibility to fracture. Thyrotoxicosis is an important risk 
factor for osteoporosis. Thyroid hormones accelerate the rate of 
bone remodelling, leading to a negative calcium balance and a net 
bone loss that accelerates the development of osteoporosis, and 
hence increases bone vulnerability to trauma[47, 55, 56]. This 
action may be mediated by a nuclear T3 receptor which has been 
found in rat and human osteoblast cell lines and in osteoclasts 
derived from an osteoclastoma[57]. Experimental studies in mice 
lacking either the thyroid hormone receptor α or β (TRα or TRβ), 
suggest bone loss is mediated by TRα [58]. Thus, thyroid hormone 
may affect bone calcium metabolism either by a direct action on 
osteoclasts, or by acting on osteoblasts which in turn mediate 
osteoclastic bone resorption[59]. TSH may also have a direct 
effect on bone formation and bone resorption, mediated via the 
TSH receptor on osteoblast and osteoclast precursors[60], 
however bone loss appeared independent of TSH levels in the 
experiments with mice lacking specific TR isoforms[58]. Post-
menopausal oestrogen-deficient women are the ones at particular 
risk of potential adverse effects of hyperthyroidism upon bone 
metabolism[61]. Even with effective antithyroid therapy a 
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complete restoration of bone mineral density (BMD) to pre-
morbid levels does not always occur[62]. 
 
1.9.Hypothyroidism:  
Hypothyroidism is a common endocrine disorder resulting from 
deficiency of thyroid hormone. It is often the primary process in 
which the thyroid gland produces insufficient amounts of thyroid 
hormone. It can also be secondary, i.e., lack of thyroid hormone 
secretion due to the failure of either adequate thyrotropin (TSH) 
secretion from the pituitary gland or thyrotropin-releasing 
hormone (TRH) from the hypothalamus (secondary or tertiary 
hypothyroidism). The patient's presentation may vary from 
asymptomatic to, rarely, coma with multisystem organ failure 
(myxoedema coma). The Whickham survey specifically sought to 
determine the incidence of thyroid disease in the general 
population[63]. Hypothyroidism, diagnosed by history and blood 
analysis, was found in more than 2% of 2800 persons tested. The 
mean age of diagnosis was 57 years, and the disease was ten-fold 
more common in women than in men. The disease is particularly 
prevalent in women older than 40 years of age. Hypothyroidism is 
prevalent in debilitated geriatric patients of both sexes[64].  
1.9.1.Causes of hypothyroidism: Worldwide, iodine deficiency 
remains the foremost cause of hypothyroidism. In the areas of 
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adequate iodine intake, autoimmune thyroid disease (Hashimoto’s 
thyroiditis) seems to be the most common cause. 
Hashimoto’s thyroiditis is part of the spectrum of autoimmune 
thyroid diseases (cf. 1.12). By strict criteria, it is a histological 
diagnosis first described by Hakaru Hashimoto, a Japanese 
surgeon working in Berlin, Germany. In this disease, there is 
continual replacement of normal thyroid tissue with lymphocytic 
and fibrous tissue – hence the term chronic lymphocytic 
thyroiditis – until insufficient thyroid tissue remains to maintain 
normal hormone production. 
Excess iodine, as in radiocontrast dyes, amiodarone, health tonics, 
and seaweed, can also cause hypothyroidism through inhibition of 
iodide organification and thyroid hormone synthesis. Most healthy 
individuals have a physiologic escape from this effect; however 
those with abnormal thyroid glands may not. These include 
patients with autoimmune thyroiditis, surgically treated Graves’ 
hyperthyroidism (subtotal thyroidectomy) and prior radioiodine 
therapy[65]. 
Medications such as amiodarone, interferon alpha, 
thalidomide[66], lithium, and stavudine have also been associated 
with primary hypothyroidism. 
Causes of hypothyroidism are summarised in table 1.9.1. 
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Table 1.9.1 Causes of hypothyroidism 
DESTRUCTIVE 
Postoperative 
Radioactive iodine 
External radiation to neck 
Infiltrative disease (e.g., sarcoidosis, amyloidosis, lymphoma, metastatic 
carcinoma) 
AUTOIMMUNE 
Hashimoto’s disease 
After Graves’ disease 
THYROIDITIS 
Subacute (e.g., viral) 
Silent 
Postpartum 
DRUG-INDUCED 
Iodides 
Lithium 
Thionamides 
HEREDITARY OR CONGENITAL 
Enzyme deficiency affecting thyroid hormone biosynthesis 
Agenesis 
Hormone resistance 
Endemic cretinism 
HYPOTHALAMIC-PITUITARY DISORDERS 
Thyrotropin-releasing hormone deficiency 
Thyroid-simulating hormone deficiency 
IDIOPATHIC 
No cause determined 
 
1.9.2.Clinical manifestations of hypothyroidism: The clinical 
spectrum of thyroid hormone deficiency ranges from the 
asymptomatic person without abnormal physical findings to the 
classic myxedoematous patient in whom the diagnosis can readily 
be made on physical examination. Physical findings are most 
striking in young, otherwise healthy patients. Old age or 
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nonthyroidal disease can commonly produce symptoms or 
physical findings that suggest thyroid disease and require thyroid 
function tests to aid in a diagnosis. 
Thyroid hormone deficiency generally causes decreased oxygen 
consumption and defects specific to individual organs. The 
common symptoms of thyroid hormone deficiency include 
lethargy and decreased physical ability. The decrease in tissue 
calorigenesis results in cold intolerance. Clinical findings in 
hypothyroidism are summarised in table 1.9.2. 
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Table 1.9.2 Clinical findings in hypothyroidism 
Affected Areas Symptoms Signs 
GENERAL Cold intolerance 
Fatigue 
Mild weight gain 
Hypothermia 
NERVOUS STSTEM Lethargy 
Memory defects 
Poor attention span 
Personality change 
Somnolence 
Slow speech 
Myxoedema wit 
Psychopathology: 
myxoedema madness 
Diminished hearing 
and taste  
Cerebellar ataxia 
NEUROMUSCULAR 
SYSTEM 
Weakness 
Muscle cramps 
Joint pain 
Delayed relaxation of 
deep tendon reflexes 
GASTROINTESTINAL 
SYSTEM 
Nausea 
Constipation 
Large tongue 
Ascites 
CARDIORESPIRATORY 
SYSTEM 
Decreased exercise 
tolerance 
Hoarse voice 
Bradycardia 
Mild hypertension 
Pericardial effusion 
Pleural effusion 
PREPRODUCTIVE 
SYSTEM 
Decreased libido 
Decreased fertility 
Menstrual disorders 
 
SKIN AND 
APPENDAGES 
Dry, rough skin 
Puffy facies 
Hair loss 
Brittle nails 
Nonpitting oedema of 
hands, face, and ankles 
Periorbital swelling  
Pallor 
Yellowish skin (i.e., 
carotenemia) 
Coarse hair 
Dry axillae 
 
1.9.3.Laboratory measurements: As with hyperthyroidism, 
measurement of the serum thyrotropin (TSH) concentration is the 
most sensitive single test for the diagnosis of hypothyroidism. A 
number of confounding factors exist when it comes to 
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determining the normal range of TSH, especially the upper normal 
limit. In practice the TSH distribution has been found to be right 
skewed. This deviation from Gaussian distribution is thought to 
be due to inclusion of individuals with underlying factors that 
confound the results. Principal among these is occult autoimmune 
thyroid disease (e.g. Hashimoto’s thyroiditis), and the population 
of individuals at the upper end of the reference range that has a 
high prevalence of antithyroperoxidase antibodies[67]. Therefore, 
reference limits have been determined by log transforming the 
TSH values, calculating the mean ± 2 SD values, and then 
exponentiating to obtain the reference limits on the original 
scale[68]. When individuals with thyroid autoantibodies, goitre, or 
a strong family history of thyroid disease are excluded, as 
proposed by The National Academy of Clinical Biochemistry 
(NACB), the upper bound of the 95% TSH concentration 
reference range decreases to between 2.5 and 3.0 mU/L (from the 
traditional 4.5-5 mU/L)[11, 68]. It has been argued that such a 
‘refined normal range’ is a better reflection of thyroid health than a 
standard population-based reference range and that elevated 
values may predict future hypothyroidism[11, 63, 68-70]. A recent 
study aimed at establishing new reference intervals for TSH and 
thyroid hormones based on NACB criteria and regular thyroid 
ultrasonography concluded that the TSH reference range should 
be narrowed to a value of approximately 4.0 mU/L as the upper-
reference limit[71]. This decreased upper bound would increase 
the sensitivity of the diagnosis of subtle hypothyroidism while 
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decreasing its specificity. Fatourechi et al showed that more than 4 
times as many patients (20.0% vs. 4.64%) would be classified as 
having elevated TSH concentrations if 3.0 mU/L rather than 5.0 
mU/L were used as the upper limit of normal[72]. The 
percentages were slightly higher in female patients than in male 
patients, and in both sexes the percentages increased with age. 
When 3.0 mU/L was used as the upper limit of normal for 
evaluating patients without clinically evident thyroid disease, 
approximately 15% of patients younger than 50 years, 17% to 
23% of patients aged 50 to 70 years, and 25% of men and 29% of 
women older than 70 years were classified as having abnormal 
TSH concentrations. These percentages were 3.8 to 5.0 times 
higher than the percentages of patients classified as having 
abnormal TSH concentrations when the traditional limit of 5.0 
mU/L is used[72].  
It is essential that physicians consider many other patient-specific 
factors, including individual patient symptoms, repeat 
measurement of TSH to confirm it is elevated and does not 
represent transient elevation or recovery from subacute thyroiditis, 
and consideration of whether the person has seronegative 
autoimmune thyroiditis. An additional clinical factor is recognition 
of the well-established individual reference range for TSH – due to 
its biovariability –  which is typically narrower than the population 
reference range[73]. Accordingly, the time of phlebotomy is also 
important, because the TSH level varies throughout the day, with 
early morning values greater than later ones, and is accentuated by 
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sleep deprivation, strenuous exercise, or working during the night 
or evening shifts[74]. The mean TSH for a given patient may be in 
either the lower or upper TSH reference range. For example, a 
patient with a confirmed TSH of 3.6 mU/L may have early 
autoimmune thyroiditis with subclinical hypothyroidism and may 
benefit from T4 therapy. However, if the history, physical 
examination, thyroid ultrasound, and thyroid antibody testing are 
all normal, it is more likely that this TSH value is normal for that 
individual, and treatment with T4 would be inappropriate. 
The sensitivity over setting the upper normal limit of TSH is most 
relevant when it comes to treating mild thyroid failure or the so-
called subclinical hypothyroidism (SCH). SCH and its 
management have been discussed in more detail under 1.14.2.4. 
The results of the recently published HUNT study are particularly 
relevant to the debate over the upper normal limit of TSH[75]. In 
this Norwegian population-based cohort study, 17311 women and 
8002 men without known thyroid or cardiovascular disease or 
diabetes mellitus were prospectively studied over a median follow-
up of 8.3 years for the association between thyrotropin levels and 
fatal CHD. The results showed that compared with women in the 
lower part of the reference range (thyrotropin level, 0.50-1.4 
mU/L), the hazard ratios for coronary death were 1.41 and 1.69 
for women in the intermediate (thyrotropin level, 1.5-2.4 mU/L) 
and higher (thyrotropin level, 2.5-3.5 mU/L) categories 
respectively; the trend was not statistically significant in men[75]. 
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If TSH levels are above the reference range, the next step would 
be to measure T4. As thyroxine is highly protein bound (>99%), 
and the levels of these binding proteins could vary by hormonal 
status, inheritance, and in various disease states, free T4 assays are 
becoming popular. As the TSH level increases early in the disease, 
an increased conversion of T4 to T3 occurs; this maintains T3 
levels. In early hypothyroidism, TSH levels are increased, T4 levels 
are normal to low, and T3 levels are normal. 
In patients with hypothalamic or pituitary dysfunction, TSH levels 
do not increase in appropriate relation to the low free T4 levels. 
The absolute levels may be in the normal or even slightly elevated 
range but inappropriately low for the severity of the hypothyroid 
state. Hence, when secondary or tertiary hypothyroidism is 
suspected, a serum TSH measurement alone is inadequate; a free 
T4 should be measured. 
1.9.4.Imaging studies: Ultrasound of the neck and thyroid can 
be used to detect nodules and infiltrative disease. It has little use in 
hypothyroidism per se unless a secondary anatomic lesion in the 
gland is of clinical concern. Hashimoto’s thyroiditis is usually 
associated with a heterogeneous image by ultrasound. It can be 
rarely associated with lymphoma of the thyroid. Serial images with 
fine-needle aspiration of suspicious nodules may be useful.  
  
Radioactive iodine uptake (RAIU) and thyroid scanning are not 
useful in hypothyroidism because these tests require some level of 
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endogenous function in the hypofunctioning gland to provide 
information. Patients with Hashimoto’s thyroiditis may have 
relatively high early uptake (after 4 h) but do not have the usual 
doubling of uptake at 24 hours consistent with an organification 
defect. 
1.9.5.Treatment: The treatment goals for hypothyroidism are the 
reversal of clinical progression and the corrections of metabolic 
derangements. Thyroid hormone is administered to supplement or 
replace endogenous production. In general, hypothyroidism can 
be adequately treated with a constant daily dose of levothyroxine. 
Clinical benefits begin in 3-5 days and level off after 4-6 weeks. 
Anticipated full replacement doses may be initiated in individuals 
who are otherwise young and healthy. In elderly patients or those 
with known ischaemic heart disease, treatment should begin with 
one fourth to one half the expected dose, and the dose should be 
adjusted in small increments no sooner than 4-6 weeks[76, 77]. 
  
The correct dose is that which restores the euthyroid state and 
relieves symptoms. In most patients these will be achieved by a 
dose of thyroxine resulting in a normal or slightly raised serum 
thyroxine concentration, a normal serum triiodothyronine 
concentration, and a normal or below normal serum thyroid 
stimulating hormone concentration[76]. Controversy exists 
concerning whether doses of thyroxine which suppress serum 
thyroid stimulating hormone concentration to below normal, i.e. 
iatrogenic subclinical hyperthyroidism, are associated with an 
  43 
increased risk of osteoporosis. However, more recent studies have 
not consistently confirmed this hypothesis except in 
postmenopausal women[61]. Achieving a TSH level within the 
reference range may be slowed because of delay of hypothalamic-
pituitary axis readaptation and may take several months. After 
dose stabilisation, patients can be monitored with annual clinical 
evaluations and TSH monitoring. Patients should be monitored 
for symptoms and signs of over treatment, which include 
tachycardia, palpitations, nervousness, tiredness, headache, 
increased excitability, sleeplessness, tremors, and possible angina.  
A recent metaanalysis of randomized controlled trials of 
thyroxine-triiodothyronine combination therapy (T4 + T3) versus 
thyroxine monotherapy (T4) for treatment of clinical 
hypothyroidism found no difference in the effectiveness of the 
combination vs. monotherapy in bodily pain, depression, fatigue, 
body weight, anxiety, quality of life, total cholesterol, LDL-C, 
HDL-C and triglyceride levels. Hence, T4 monotherapy remains 
the treatment of choice[78].  
Hypothyroidism in pregnancy is associated with preeclampsia, 
anaemia, postpartum haemorrhage, cardiac ventricular 
dysfunction, spontaneous abortion, low birth weight, impaired 
cognitive development, and foetal mortality. Even mild disease 
may be associated with adverse affects for offspring. Increased 
dosage requirements should be anticipated during pregnancy, 
especially in the first and second trimesters. Recent studies have 
  44 
suggested that patients with hypothyroidism should augment the 
thyroxine dose by 30% at the confirmation of pregnancy, 
followed by adjustments according to TSH levels. For previously 
diagnosed women serum TSH should be measured every 3-4 
weeks during the first half of pregnancy and every 6 weeks 
thereafter.  thyroxine dose should be adjusted to maintain a 
serum TSH less than 2.5 mU/L. TSH and free T4 levels should 
be measured every 3-4 weeks after every dose adjustment[79]. 
Surgery is indicated for large goitres that compromise 
tracheoesophageal function; surgery is rarely needed in patients 
with hypothyroidism. 
1.9.6.Complications:  
Coma, as an end stage of myxoedema, was described by Ord in 
1880. An effective approach is to use intravenous thyroxine at a 
dose of 4 mcg/kg of lean body weight, or approximately 200-250 
mcg as a bolus in a single or divided dose, depending on the 
patient's risk of cardiac disease followed by 100 mcg 24 hours 
later and then 50 mcg daily IV or PO along with stress doses of 
intravenous glucocorticoids. Adjustment of the dose can then be 
made based on clinical and laboratory along with stress doses of 
intravenous glucocorticoids. Use of intravenous triiodothyronine 
is controversial and based on expert opinion. It has a higher 
frequency of adverse cardiac events and is generally reserved for 
patients who are not improving clinically on T4. T3 can be given 
initially as a 10 mcg IV bolus and repeated every 8-12 hours until 
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the patient can take maintenance oral doses of T4. Advanced age, 
high dose T4 therapy, and cardiac complications have the highest 
associations with mortality[80]. 
Thyroid hormone replacement can precipitate adrenal crises in 
patients with untreated adrenal insufficiency. If suspected, the 
presence of adrenal insufficiency should be confirmed or ruled 
out and should be treated prior to treatment of hypothyroidism. 
Patients should be advised that vision may temporarily worsen 
when starting hormone therapy. Rarely, pseudotumour cerebri 
occurs[81]. 
1.10. Subclinical thyroid disease: 
Subclinical thyroid disease is defined as an abnormal serum TSH 
level and free thyroxine and triiodothyronine levels within their 
reference ranges. The symptoms, signs, and laboratory 
abnormalities associated with overt hyperthyroidism and 
hypothyroidism as reviewed in previous sections are well known 
to clinicians. Both conditions are unequivocally associated with 
morbidity and, occasionally, mortality, and no one would dispute 
the importance of timely diagnosis and therapy. In contrast, 
subclinical hyperthyroidism and hypothyroidism have subtle 
clinical manifestations at most, and the importance of timely 
diagnosis and treatment continue to be contentious subjects of 
studies, position papers, and editorials[82, 83]. The central issues 
are whether subclinical thyroid diseases are of sufficient clinical 
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importance to warrant screening and whether, once these 
conditions are detected by an abnormal serum thyrotropin value 
and confirmed by further testing, therapy is justified. Because 
reliable TSH assays have been available for more than 20 years, 
one would think that adequate data would have been amassed by 
now to answer these questions definitively. However, this is not 
the case, and the debate continues. Subclinical hyperthyroidism 
and subclinical hypothyroidism have been discussed under 
1.14.1.3 and 1.14.2.4., especially with regard to their effects on 
the cardiovascular system.  
 
1.11.Thyroiditis: 
1.11.1. Subacute thyroiditis: Subacute thyroiditis is a self-limiting 
thyroid condition associated with a triphasic clinical course of 
hyperthyroidism, hypothyroidism, and return to normal thyroid 
function. Subacute thyroiditis may be responsible for 15-20% of 
patients presenting with thyrotoxicosis and 10% of patients 
presenting with hypothyroidism. Recognizing this condition is 
important because it is self-limiting, and no specific therapy, such 
as antithyroid or thyroid hormone replacement therapy, is 
necessary in most patients. The high thyroid hormone levels are a 
result of destruction of the thyroid follicle and release of 
preformed thyroid hormone into the circulation. Eventually, 
thyroid hormone is depleted and the patient may become 
hypothyroid. Often the hypothyroidism is mild, and no thyroid 
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hormone therapy is required unless the patient has signs or 
symptoms of hypothyroidism. The hypothyroid phase may last 
up to 2 months. Ninety to 95% of patients return to normal 
thyroid function. 
The 3 types of subacute thyroiditis are subacute granulomatous, 
also referred to as painful or de Quervain’s thyroiditis; subacute 
painless thyroiditis, which is silent and also referred to 
as lymphocytic or silent thyroiditis; and postpartum thyroiditis. 
The aetiology of each of these conditions is different, but all of 
the conditions follow the same clinical course, including 6-8 
weeks of thyrotoxicosis, 2-4 months of mild hypothyroidism, 
and, finally, a return to the euthyroid state in 90-95% or more of 
the patients. A patient may experience one or more of these 
phases. 
The most accepted aetiology of de Quervain’s thyroiditis is a viral 
illness. A genetic predisposition clearly exists and patients with 
HLA-B35 have a significantly increased risk of developing this 
condition[84]. A weak association with HLA-DRw8 has also 
been reported[85]. 
Silent thyroiditis is associated with an excess of HLA-DR3[86]. 
This association links silent thyroiditis to autoimmune thyroiditis 
rather than to de Quervain’s thyroiditis[87]. Silent thyroiditis has 
also been reported in conjunction with amiodarone[88] and 
lithium, and with the use of interferon-α in the treatment of 
hepatitis C patients[89, 90]. 
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Like silent thyroiditis, postpartum thyroiditis is associated with 
HLA-DR3, but an association with DR5 is also observed[86]. 
This postpartum entity occurs in 5% to 9% of all 
pregnancies[91]. These observations are of particular interest for 
the probable autoimmune nature of this and the classic form of 
silent thyroiditis, as it is well established that many autoimmune 
diseases flare up during the postpartum period after resolution of 
the immune suppression normally seen to occur during 
pregnancy. Higher ratios of helper (CD4+) to suppressor 
(CD8+) T cells seen in the postpregnancy state may play a critical 
role in the development of this postpartum dysfunction[91]. 
Patients with type 1 diabetes mellitus are especially prone to the 
development of postpartum thyroiditis; as many as 25% 
experience this disorder[92]. 
1.11.2. Riedel’s thyroiditis: Riedel’s thyroiditis is an unusual and 
rare form of thyroid disease, which is characterized by extensive 
fibrosis of the thyroid gland. In these patients, the gland is hard, 
woody in consistency, and often fixed to the adjacent tissues. 
Occasionally, the gland may be asymmetric, presenting as a 
unilateral mass. In many patients with Riedel’s thyroiditis, local 
symptoms, including hoarseness (recurrent laryngeal nerve 
involvement) or dysphagia, are present. The aetiology is unclear, 
but it may represent a variant of Hashimoto’s thyroiditis, as 
evidenced by the mononuclear infiltrate, the detection of thyroid-
specific autoantibodies in many patients, and the response to 
glucocorticoid treatment[93]. Surgical treatment may be required 
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if there are significant local symptoms or evidence of tracheal 
compression. Corticosteroids occasionally have been helpful in 
reducing the goitre size and alleviating local symptoms[94]. 
1.12. Amiodarone and thyroid dysfunction: Amiodarone is a 
potent antiarrhythmic drug that is used to treat ventricular and 
supraventricular tachyarrhythmias. It is an iodine-rich compound 
with some structural similarity to thyroxine. Amiodarone contains 
approximately 37% iodine by weight. Each 200 mg tablet is 
estimated to contain about 75 mg of organic iodide, 8-17% of 
which is released as free iodide. Standard maintenance therapy 
with 200 mg amiodarone can provide more than 100 times the 
daily iodine requirement. It is highly lipid-soluble and is 
concentrated in the adipose tissue, muscle, liver, lung, and thyroid 
gland. Total body iodine stores remain increased for up to 9 
months after discontinuation of the drug. 
Amiodarone effects on thyroid function are mainly related to the 
inhibition of 5'-deiodinase activity resulting in a decrease in the 
generation of T3 from T4 with a consequent increase in rT3 
production and a decrease in its clearance[95]. 
Table 1.12.1 Effects of amiodarone on the thyroid gland 
Intrinsic drug effect  Iodine-induced effects  
Blockade of thyroid hormone entry 
into cells 
 Failure to escape from Wolff-
Chaikoff effect 
Inhibition of type I and type II 5’-
deiodinase 
Iodine-induced potentiation of 
thyroid autoimmunity 
Decreased T3 binding to its receptor Unregulated hormone synthesis (Jod-
Basedow effect) 
Thyroid cytotoxicity  
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Effects of amiodarone on thyroid function tests in euthyroid 
subjects are summarised in table 1.12.2. 
Table 1.12.2. Effects of amiodarone on thyroid function tests in euthyroid 
subjects 
Thyroid Hormone  Acute effects (up to 3 
months)  
Chronic effects  
(> 3 months)  
Total and free T4 range ↑50%  Remains ↑ 20-40% of 
baseline 
Total and free T3  ↓ 15-20%, remains in 
low-normal range 
Remains ↓ 20%, 
remains in low-normal 
rT3 ↑ > 200% Remains ↑ > 150% 
TSH ↑ 20-50%, transient, 
generally remains < 20 
mU/L 
Normal 
 
Although most patients remain clinically euthyroid, a significant 
minority (up to 15% of patients in the UK and the USA) develop 
amiodarone induced hypothyroidism or thyrotoxicosis[96]. 
1.12.1. Amiodarone induced thyrotoxicosis (AIT): Less 
common than amiodarone induced hypothyroidism in iodine 
replete areas such as the UK and USA (< 2% v 13%), the 
pathogenesis of amiodarone induced thyrotoxicosis is more 
complex and the diagnosis and treatment much more difficult. 
AIT occurs more frequently in men and in iodine deficient areas, 
but there is no relation between the daily or cumulative dose of 
amiodarone and the incidence of AIT. The onset of AIT is often 
acute and may occur several months after the discontinuation of 
treatment. Spontaneous remissions are common[96]. 
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There are two main forms of AIT (table 1.12.1) that have different 
aetiologies. Type 1 AIT occurs in patients with underlying thyroid 
pathology, such as latent Graves’ disease or nodular goitre. This 
iodide induced thyrotoxicosis, an example of the Jod-Basedow 
phenomenon, is identical to that seen in patients with endemic 
iodine deficient goitre who are then given iodide replacement, thus 
explaining why thyrotoxicosis is more common in iodine depleted 
areas. In contrast, type 2 AIT occurs in an apparently normal 
thyroid, and results from a direct toxic effect of amiodarone 
causing a subacute destructive thyroiditis with consequent leakage 
of preformed thyroid hormones into the circulation[96]. 
Table 1.12.1. Pathogenesis and clinical features of amiodarone induced 
thyrotoxicosis  
 Type 1 Type 2 
Underlying thyroid 
abnormality  
Yes No 
Pathogenetic 
mechanism  
Excessive hormone 
synthesis due to iodine 
excess  
Excessive release of 
preformed hormones 
due to thyroid 
destruction 
Goitre  Multinodular or diffuse 
goitre normally present 
Occasionally small, 
diffuse, firm, 
sometimes tender 
Thyroidal radioiodine 
uptake  
Normal/raised  Low/absent 
Serum IL-6 Normal/slightly raised Profoundly raised 
Thyroid ultrasound Nodular, hypoechoic, 
increased volume 
Normal 
 
In AIT the drug should be stopped, if possible, though this is 
often impractical because of the underlying cardiac disorder. 
Discontinuation of amiodarone will not have an acute effect 
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because of its storage and prolonged half-life. High doses of 
antithyroid drugs can be used in type 1 AIT but are often 
ineffective. Potassium perchlorate, 200 mg every 6 h, has been 
used to reduce thyroidal iodide content. Perchlorate treatment has 
been associated with agranulocytosis, though the risk appears 
relatively low with short-term use. Glucocorticoids, administered 
as for subacute thyroiditis, are beneficial in type 2 AIT. Lithium 
blocks thyroid hormone release and can provide modest benefit. 
Thyroidectomy rapidly decreases thyroid hormone levels and may 
be the most effective long-term solution, if the patient can 
undergo the procedure safely[5]. In patients with a history of AIT 
in whom amiodarone becomes necessary after it has been 
discontinued, ablation of the thyroid with radioiodine before 
resuming amiodarone should be strongly considered[97]. 
1.12.2. Amiodarone induced hypothyroidism (AIH): 
Amiodarone-induced hypothyroidism (AIH) occurs more 
frequently than AIT in iodine-replete areas. The risk of developing 
AIH is independent of the daily or cumulative dose of 
amiodarone, but is enhanced in elderly and female patients with a 
M:F ratio of 1:1.551[95, 96]. This is to be expected as autoimmune 
thyroid disease is the principal risk factor for the development of 
AIH and is particularly common in these patient groups[96]. 
The most likely explanation for the development of AIH is an 
inability of the thyroid to escape from the acute inhibitory effects 
of iodine on hormone release and synthesis. This may reflect 
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underlying thyroid disease, as AIH is also a well recognised 
outcome in patients with subclinical autoimmune thyroiditis given 
excess iodine and generally occurs relatively early (3 to 12 months) 
after starting treatment with amiodarone. It is also possible that 
excess iodine may exacerbate preexisting autoimmune thyroiditis 
directly in some patients, particularly those from areas of low 
dietary iodine intake[96]. 
The diagnosis of hypothyroidism is usually straightforward. The 
clinical features are not affected by amiodarone, although most 
patients have very few symptoms, most commonly increased 
lethargy. The diagnosis is confirmed by finding a raised TSH 
concentration, usually above 20 mU/L, in combination with low 
T4 or fT4. Low T3 or FT3 concentrations are unreliable indicators 
of AIH as they may occur in euthyroid patients during amiodarone 
treatment. A goitre is found in about 20% of patients with AIH in 
iodine replete areas, but most of these goitres predate the start of 
amiodarone treatment[96]. 
Many patients without preexisting thyroid disease will become 
euthyroid within two to four months of stopping amiodarone, but 
permanent hypothyroidism requiring T4 replacement is common 
in patients with thyroid antibodies[98]. By far the safest, quickest, 
and most reliable treatment for hypothyroidism is to continue 
amiodarone and to add T4, increasing the dose at monthly 
intervals until the TSH concentration is well within the normal 
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range and symptoms attributable to hypothyroidism have 
resolved[96]. 
1.13. Nonthyroidal illness 
The frequency with which thyroid disease is encountered in the 
general population, the ease with which it is excluded in otherwise 
healthy persons, and the poor specificity of the individual signs 
and symptoms of thyroid dysfunction all have contributed to the 
practice of screening for thyroid disease in ill patients, in the 
search for a readily reversible component to the presenting illness. 
The result is the recognition of multiple abnormalities in parameters 
of thyroid function in these patients. Based on the conviction that 
patients with these abnormalities are not hypothyroid despite the 
low hormone levels in blood, the condition has been called the 
euthyroid sick syndrome[99]. An alternative designation, which does 
not presume the metabolic status of the patient, is nonthyroidal 
illness (NTI)[100]. Although early cross-sectional studies in such 
patients had revealed a baffling collection of low, normal, or high 
values for total and free thyroid hormones, subsequent work has 
suggested a continuum of change, within which a given patient’s 
status is determined by the severity and duration of illness as well 
as the presence of mitigating influences that are associated with 
the specific underlying disorder. Hence, an early and dramatic 
reduction in serum total and free triiodothyronine levels occurs, 
followed, in cases of sufficient severity, by a depression in serum 
total thyroxine and variable changes in serum free thyroxine levels. 
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Concurrent with decrements in levels of circulating thyroid 
hormones, a seemingly inept response is seen at the hypothalamic-
pituitary level; this persists until the recovery phase of the 
underlying illness, at which time a rise in TSH to even 
supranormal levels may be seen that coincides with a rapid 
recovery in T4 and T3 levels[101]. This decrease in serum thyroid 
hormone levels is seen in starvation, sepsis, surgery, myocardial 
infarction, cardiopulmonary bypass, poorly controlled diabetes 
mellitus, bone marrow transplantation, and probably any severe 
illness[100].  
Measurement of serum TSH, free T4, and free T3 levels by direct 
equilibrium dialysis/RIA methods probably yield most accurate 
information in the setting of NTI. Patients with low free T4 by 
these methods and normal or low TSH have secondary 
hypothyroidism. This may be due to NTI per se, drugs 
administered for treatment of NTI, or associated pituitary or 
hypothalamic disease; the latter consideration may require 
evaluation of cortisol reserve, prolactin, and/or gonadotropins. A 
serum TSH level above 20-25 mU/L probably reflects primary 
hypothyroidism; accompanying findings of goitre, low free T4, and 
positive antithyroid antibodies help establish the diagnosis. An 
elevated serum concentration of reverse T3 argues against 
hypothyroidism[102]. 
The following mechanisms have been proposed to explain the 
abnormalities in thyroid hormone levels during a NTI[103]: 
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Figure1.6: Influence of the stage and the severity of nonthyroidal illness on 
thyroid function parameters (adapted from Becker’s Principles and Practice of 
Endocrinology and Metabolism, 3rd edition, 2002). 
• Accuracy of test assays in nonthyroidal illness: 
Abnormalities of thyroid function test results might 
represent test artifacts or true abnormalities 
• Inhibition of thyroid hormone binding to thyroid-binding 
proteins and tissues, thus preventing tests from 
appropriately reflecting free hormone levels. This inhibitor 
is associated with the nonesterified fatty acid (NEFA) 
fraction in the serum. Contrary to this proposition, 
substantial evidence indicates that, in an in vivo state, the 
levels of binding inhibitors do not reach levels sufficient to 
influence the circulating levels of free T4, even in patients 
who are severely ill. Also, some studies have failed to 
demonstrate an existing binding inhibitor. 
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• Cytokines are thought to play a role in NTI—particularly 
IL-1, IL-6, TNFα, and interferon-β. Cytokines are thought 
to affect the hypothalamus, the pituitary, or other tissues, 
inhibiting production of TSH, TRH, thyroglobulin, T3, and 
thyroid-binding globulins. Cytokines are also thought to 
decrease the activity of type I deiodinase and to decrease 
the binding capacity of T3 nuclear receptors. 
• Deiodination: Peripheral deiodination of T4 to T3 is 
impaired, largely secondary to decreased activity of type I 
deiodinase enzyme, which deiodinates T4 to T3.  
• Inhibition of TRH and TSH secretion: Cytokines, cortisol, 
and leptin, as well as changes in brain thyroid hormone 
metabolism, affect inhibition and secretion of TRH and 
TSH. 
• Serum factors, such as bilirubin, NEFA, furanoic acid, 
hippuric acid, and indoxyl sulphate, which are present in 
various NTIs, have been shown to inhibit transport of 
thyroid hormones. 
• Thyroxine-binding globulin decrease and desialation: 
Diminished T4 in NTI has been proposed to be due to low 
TBG caused by protease cleavage at inflammatory sites in 
acute inflammatory conditions. One other hypothesis for 
the cause of disproportionately low serum T4 
concentrations in patients with NTI is the presence of 
abnormal serum binding due to desialation of TBG[103]. 
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Given the clinical context and pattern of laboratory values, the 
diagnosis of NTI is frequently presumptive. Only resolution of the 
test results with clinical recovery can clearly establish this disorder. 
Treatment of NTI with thyroid hormone (T4 and/or T3) is 
controversial, but most authorities recommend monitoring the 
patient's thyroid function tests during recovery, without 
administering thyroid hormone, unless there is historic or clinical 
evidence suggestive of hypothyroidism. There is no prospective 
study to date demonstrating benefit or harm of thyroid hormone 
replacement in NTI. Dr De-Groot has supported the notion that 
nonthyroidal illness syndrome is a manifestation of hypothalamic-
pituitary dysfunction, and in view of current evidence, he 
proposed that treatment  should be considered with appropriate 
replacement therapies such as pituitary hormones 
and hypothalamic factors in addition to thyroid hormones[104]. 
De-Groot also points out that if effective, thyroid hormone 
replacement will be one of many beneficial treatments given to the 
patient, rather than a single magic bullet, which would reverse all 
the metabolic changes going wrong in these severely ill 
patients[104]. 
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1.14. Thyroid and the cardiovascular system:  
Thyroid dysfunction syndromes (hyper and hypothyroidism) are 
known to affect the cardiovascular system in a number of 
ways[105].  
Whilst the acute effects of thyroid dysfunction on the 
cardiovascular system are more readily detectable – especially with 
hyperthyroidism – the evidence on the long term effects of thyroid 
dysfunction on the heart and on the cardiovascular outcomes is 
less clear. This is particularly true of the mild or subclinical forms 
of hypo and hyperthyroidism. For example, a 20-yr follow-up 
study of the original Whickham Survey[63] found no association 
between initial hypothyroidism, raised serum TSH levels, or 
antithyroid antibodies and the development of coronary artery 
disease. However, the more recent Rotterdam Study[106] 
concluded that patients with subclinical hypothyroidism have a 
significantly increased prevalence of aortic atherosclerosis and 
myocardial infarctions. The common finding between the 
Whickham Survey and Rotterdam study was that thyroid 
autoimmunity itself was not associated with myocardial infarction 
or aortic atherosclerosis. 
The following sections of this chapter look at our current 
knowledge of both short and long term effects of thyroid 
dysfunction – including the subclinical forms – on the 
cardiovascular system. Although it has been asserted by various 
authors that ‘subclinical’ is a misnomer and ‘mild thyroid 
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dysfunction’ is a more appropriate term than ‘subclinical’ [82, 107, 
108], this thesis uses the term ‘subclinical’ in line with the current 
trend in the literature. However, it is acknowledged that there is 
compelling evidence – as detailed later in this chapter – that these 
mild forms of thyroid dysfunction have significant clinical effects 
and it may be more appropriate to use ‘mild hyperthyroidism’ and 
‘mild hypothyroidism’ instead of ‘subclinical hyperthyroidism’ and 
‘subclinical hypothyroidism’ respectively, in future. 
1.14.1. Hyperthyroidism and the cardiovascular system: 
1.14.1.1. Overt hyperthyroidism: 
Excess thyroid hormone causes tachycardia, palpitations, with 
some degree of exercise impairment and a widened pulse pressure. 
These changes occur independently of the cause of the 
hyperthyroidism[109-111]. The changes in heart rate result from 
both an increase in sympathetic tone and a decrease in 
parasympathetic tone[112-114]. Tachycardia, with heart rates 
greater than 90 beats per minute, is common at rest and during 
sleep; in addition, the normal increase in heart rate during exercise 
is exaggerated[114]. In a study of 880 patients of widely varying 
ages, resting tachycardia was second only to goitre as the most 
common sign of hyperthyroidism[115]. 
In patients with hyperthyroidism, cardiac output is 50 to 300 
percent higher than in normal subjects. The increase is due to the 
combined effects of a decrease in systemic vascular resistance, an 
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increase in resting heart rate, increases in left ventricular 
contractility and ejection fraction, and an increase in blood volume 
[105]. The importance of the contribution of decreased systemic 
vascular resistance to the increase in systemic blood flow in 
patients with hyperthyroidism is evidenced by the results of 
studies in which the administration of arterial vasoconstrictors, 
atropine and phenylephrine, decreased peripheral blood flow and 
cardiac output by 34 percent in patients with hyperthyroidism but 
had no effect in normal subjects[116, 117]. 
Patients with hyperthyroidism have increased left ventricular 
systolic and diastolic contractile function, a finding consistent with 
changes in the expression of contractile and calcium-regulatory 
proteins, as described by Kiss et al and Ojamaa et al[118, 119]. The 
rate of increase in intraventricular pressure during systole, the left 
ventricular ejection fraction, and the rate of blood flow across the 
aortic valve are all increased[120].  Similarly, the rates of chamber 
relaxation (isovolumic relaxation) and left ventricular filling, 
measured as the flow across the mitral valve during diastole, are 
increased[110]. Administration of a β-adrenergic–receptor 
antagonist to patients with hyperthyroidism slows the heart rate 
but does not alter systolic or diastolic contractile performance[110, 
111] confirming that thyroid hormone acts directly on cardiac 
muscle[119, 121, 122]. 
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1.14.1.2. Cardiac arrhythmias associated with hyperthyroidism: 
Sinus tachycardia is the most common arrhythmia associated with 
thyroid hormone excess. Other rhythm disturbances frequently 
associated with thyrotoxicosis include atrial premature 
contractions and atrial fibrillation. Less often, patients may present 
with paroxysmal atrial tachycardia or atrial flutter. Ventricular 
premature contractions and ventricular tachyarrhythmias are 
rare[123]. 
Atrial fibrillation occurs in 5% to 15% of hyperthyroid 
patients[105]. Higher rates may be found in patients with known 
or suspected heart disease, or at risk for heart disease such as the 
elderly or men. TSH should be routinely checked in all patients 
with AF, as it may be the only manifestation of 
hyperthyroidism[123]. 
Whether patients with hyperthyroidism who have atrial fibrillation 
should receive anticoagulant therapy is controversial[105]. 
Individual risk-benefit assessment for each patient must weigh the 
risk of bleeding during anticoagulant treatment against the risk of 
systemic embolisation[124]. In a retrospective study of 610 
patients with hyperthyroidism, age – rather than the presence of 
atrial fibrillation – was the main risk factor for embolisation[125]. 
In another study, of 11354 patients with hyperthyroidism, 288 had 
atrial fibrillation, of whom 6 had systemic embolisation. Of these 
six patients, five were more than 50 years of age and had atrial 
fibrillation for more than six months, and four had congestive 
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heart failure. In younger patients with hyperthyroidism and atrial 
fibrillation who do not have other heart disease, hypertension, or 
independent risk factors for embolisation, the risk of anticoagulant 
therapy probably outweighs the benefits[124]. Conversely, in older 
patients who are known or suspected to have heart disease, or in 
those with chronic atrial fibrillation, anticoagulant therapy should 
be initiated[105]. 
1.14.1.3. Subclinical hyperthyroidism:  
Subclinical hyperthyroidism is characterized by the presence of low 
or undetectable plasma TSH concentrations and normal circulating 
free thyroid hormones. Subclinical hyperthyroidism is often 
present in patients treated with TSH-suppressive doses of 
thyroxine for thyroid nodular disease or as postoperative 
treatment for differentiated thyroid carcinoma to prevent local 
and/or metastatic progression (exogenous or iatrogenic subclinical 
hyperthyroidism). However, it is also seen in patients with 
autonomously functioning thyroid nodule or multinodular goitre 
(endogenous subclinical hyperthyroidism). Its prevalence, in 
several large community and clinical surveys, has been reported to 
range from 2–16%[126].  
Alterations in cardiac Haemodynamic have been reported in some, 
but not all, studies of patients with subclinical 
hyperthyroidism[105]. Although the data concerning the increase 
of heart rate and the incidence of supraventricular arrhythmias in 
patients with subclinical hyperthyroidism are not consistent[127-
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130], it seems that the elderly population is particularly susceptible 
to the arrhythmogenic effect of subclinical hyperthyroidism. Sawin 
et al in their 10 year follow up of 2007 men and women aged 60 or 
more, demonstrated that a low serum thyrotropin concentration 
(≤ 0.1 mU/L) was associated with a threefold higher risk of 
developing atrial fibrillation in the subsequent decade[131]. Their 
findings concur with those of the more recently analysed data 
from the Cardiovascular Health Study[132]. Therefore, Serum 
thyrotropin should be measured in all elderly patients with systolic 
hypertension, a widened pulse pressure, recent-onset angina, atrial 
fibrillation, or an exacerbation of underlying ischaemic heart 
disease[105, 113]. Because of increased morbidity and mortality 
from thromboembolic events associated with atrial fibrillation, 
subclinical hyperthyroidism in older patients may be considered a 
risk factor for thromboembolism[107]. 
Subclinical hyperthyroidism has also been shown to affect cardiac 
morphology and function in the young and the middle-aged 
through  increased heart rate and LV mass, enhanced LV function, 
and impaired LV diastolic filling[107]. The increase in LV mass is 
mainly the consequence of the long-term increase in cardiac 
workload, and is responsible for the co-existing diastolic 
dysfunction and impaired systolic function during exercise [133]. 
These abnormalities were significantly reverted by ß-blocking 
drugs[111]. The above effects on the cardiovascular system seem 
to be consistent with both endogenous and exogenous subclinical 
hyperthyroidism[107, 134]. Recently, Patanè et al presented a case 
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of acute myocardial infarction without significant coronary 
stenoses associated with subclinical hyperthyroidism[135]. 
Furthermore, an increase in the prevalence of symptoms and signs 
of thyroid hormone excess and impaired quality of life is seen in 
this age group[107]. Current recommendations for the treatment 
of subclinical hyperthyroidism are to observe and monitor patients 
with partial TSH suppression (0.1– 0.4 mU/L), but to  treat 
patients with complete TSH suppression (<0.1 mU/L)[82]. 
 
1.14.2. Hypothyroidism and the cardiovascular system: 
1.14.2.1. Hypothyroidism and atherosclerosis 
“There was oedema of the skin. . . much serous effusion in the pericardium. . . 
the heart was large. . . the arteries were everywhere thickened, the larger ones 
atheromatous.” [Dr. William Smith Greenfield, 1878].[136] 
This autopsy finding of diffuse atherosclerosis in a 58-yrold 
woman was published as an appendix to William Ord’s classical 
description of the syndrome of myxoedema. Soon thereafter, the 
hypothesis of a causal relationship between hypothyroidism and 
atherosclerosis was first raised in 1883 by E. Theodor Kocher 
[137], who noted that arteriosclerosis commonly occurred after 
thyroid extirpation. 
In 1967 the first case-control study by Vanhaelst et al. [138] 
compared autopsy findings in 25 patients with myxoedema with 
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50 age-matched controls and found a greater prevalence and 
severity of coronary atherosclerosis in the hypothyroid group. In a 
subsequent case-control study performed by Steinberg in 
1968[139], women with myxoedema had more severe coronary 
artery disease on autopsy than did age matched women without 
myxoedema. However, this difference was present only between 
hypertensive cases and controls, with similar degrees of 
atherosclerosis between normotensive hypothyroid women and 
normotensive controls. Another autopsy study[140] took the 
converse approach, examining the thyroid glands of 55 patients 
who had died of atherosclerotic disease. All of the thyroids were 
found to have some abnormality, in size or cellular structure, 
compared with no abnormalities in four controls without 
atherosclerosis. Although these studies were conducted before the 
era of TSH testing to confirm the diagnosis of hypothyroidism, 
they suggested that the relationship between hypothyroidism and 
atherosclerotic disease exceeded the statistical coincidence of these 
two common processes[77]. 
The association between hypothyroidism and atherosclerosis has 
also been shown in living patients. A study of patients undergoing 
coronary angiography demonstrated that those who had 
inadequate therapy for hypothyroidism were more likely to have 
angiographic progression of coronary artery disease than those 
with adequate replacement[141]. However, this study should be 
interpreted with caution because it is based on only 10 individuals 
and potentially subject to bias from the practices of referring 
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physicians, who may have been reluctant to increase the dose of 
T4 in patients with more symptomatic or severe atherosclerotic 
disease[142]. In a hospital-based study, men and women with a 
TSH level of 4.0 mU/L or greater had higher prevalence of 
coronary artery disease than age matched controls (48% vs. 38% 
for men and 37% vs. 20% for women), although this was 
statistically significant only for women[143]. 
1.14.2.2. Hypothyroidism and cardiovascular risk markers 
Elevated levels of total cholesterol, LDL cholesterol, and 
apolipoprotein B are well documented features of overt 
hypothyroidism[144]. Early studies in humans with 
hypothyroidism, using isotopically labelled LDL, demonstrated a 
prolonged half-life of LDL cholesterol because of decreased 
catabolism, an effect that was reversible with T4 therapy[145]. 
Additional data in human fibroblasts verified that the T3-induced 
increase in LDL degradation was mediated through an increase in 
LDL receptor number, without any change in the affinity of LDL 
for its receptor. A specific effect of thyroid hormone on the LDL 
receptor was suggested by a lack of T3 effect on LDL 
concentration in cultured cells without LDL receptors[146]. These 
findings were supported by an in vivo study in a hypothyroid 
woman whose receptor mediated LDL catabolism was reduced, 
compared with euthyroid controls, with significant improvement 
after T4 replacement therapy[147]. 
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Studies have also shown that hypothyroidism causes qualitative 
changes in circulating lipoproteins that increase their 
atherogenicity. Two studies have shown that LDL is more 
susceptible to oxidation in patients with hypothyroidism, with 
normalisation after restoration of the euthyroid state[148, 149]. 
Increased levels of lipoprotein(a) [Lp(a)], a particularly atherogenic 
LDL variant in which apolipoprotein(a) and apolipoprotein B 
(Apo B) are covalently bound, have also been reported in 
hypothyroidism, compared with euthyroid controls. Several 
studies have shown decreases in the Lp(a) concentration after T4 
treatment of hypothyroid patients[150-154]. However, other 
reports have not confirmed this relationship[155, 156]. Clinical 
trials have not demonstrated an effect of T4 on Lp(a) levels in 
subclinical hypothyroidism[153-155, 157, 158], with the exception 
of one trial, which showed a decrease in Lp(a)[159]. Ito et al 
studied the effect of T4 therapy on lipid profiles of patients with 
overt and subclinical hypothyroisim, including their non-HDL-C 
(a measure of total cholesterol minus HDL-C)[154]. They showed 
that After T4 replacement, the serum concentrations of all 
lipoproteins, except Lp(a), were significantly decreased in patients 
with overt hypothyroidism. In patients with subclinical 
hypothyroidism, the serum concentrations of total cholesterol, 
non-HDL-C, remnant-like particle cholesterol, and Apo B were 
significantly decreased, whereas no significant changes in the 
serum concentrations of low-density lipoprotein cholesterol, 
HDL-C, triglycerides, apolipoprotein A-I, and Lp(a) were 
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observed. In all 39 patients, the reduction in the non-HDL-C 
levels correlated with the reduction in the low-density lipoprotein 
cholesterol, remnant-like particle cholesterol, and Apo B levels. 
However, the reduction in the non-HDL-C levels did not correlate 
with the reduction in the HDL-C, Lp(a), and apolipoprotein A-I 
levels. These results suggest that altered serum concentrations of 
non-HDL-C in hypothyroidism may be related to the disturbed 
metabolism of low-density lipoprotein, remnant lipoprotein, and 
Apo B[154]. 
Additional potentially atherogenic effects of hypothyroidism on 
lipid metabolism include a reversible reduction in clearance of 
chylomicron remnants[160]; reduced activity of cholesteryl ester 
transfer protein, which is involved in reverse cholesterol transport 
pathway[161, 162]; and decreased activity of hepatic lipase and 
lipoprotein lipase[163, 164]. 
Several studies have demonstrated elevated homocysteine levels in 
hypothyroidism[165-167], with improvement after T4 
replacement[168-170]. This is likely to be caused by impaired renal 
homocysteine clearance, although an effect of thyroid hormone on 
enzymes involved in folate metabolism has also been 
proposed[169, 171]. The magnitude of decline in homocysteine 
levels after T4 treatment is sufficient to lower cardiovascular risk, 
with a decrease of 2–5 µmol/L when hypothyroid patients were 
treated with T4 to a level suppressing the serum TSH 
concentration[168, 169, 171]. One study of patients with 
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spontaneous hypothyroidism showed a decrease of 4.6 µmol/L on 
restoring the euthyroid state[170]. In contrast, there are now 
considerable data showing that subclinical hypothyroidism is not 
associated with hyperhomocysteinaemia. Three case-control 
studies[167, 172, 173] have reported no difference in 
homocysteine levels between individuals with subclinical 
hypothyroidism and euthyroid controls. Furthermore, Christ-Crain 
et al.[167] found no significant change in homocysteine levels after 
treatment of subclinical hypothyroidism. 
C-reactive protein (CRP), another cardiovascular risk factor, has 
also been studied in relation to hypothyroidism. Christ-Crain et al. 
[167] measured CRP in 61 overtly hypothyroid and 63 subclinically 
hypothyroid patients and compared them with 40 euthyroid 
control subjects. CRP levels were significantly higher in both 
hypothyroid groups, compared with controls. However, CRP 
levels did not decrease with T4 treatment of the subclinically 
hypothyroid patients. 
Davies et al showed a reverse statistical relation between serum 
interleukin 6 (IL-6) concentrations and alterations in circulating 
thyroid hormone concentrations seen in in-patients with non-
thyroidal illness[174]. This negative correlation was also supported 
by Yamazaki et al who suggested that IL-6 in vivo would be 
capable of inhibiting the synthesis and release of T4 and, to a 
greater extent, T3 from the thyroid gland[175]. The relationship 
between thyroid status and IL-6 seems to warrant further research, 
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especially given the results of a recent study showing that among 
the inflammatory markers, IL-6 was the strongest predictor for 
CHF[176]. 
Some studies have shown that insulin resistance or the metabolic 
syndrome are independent risk factors for cardiovascular disease 
even in individuals  without diabetes[177]. Although 
hypothyroidism does not appear to cause insulin resistance[178], 
Bakker et al.[179] postulated that relatively lower thyroid hormone 
levels might amplify the increased cardiovascular risk associated 
with insulin resistance. Their study did confirm that insulin-
resistant subjects with high normal TSH levels had higher LDL 
cholesterol concentrations, whereas among insulin-sensitive 
individuals, TSH concentration was not associated with any 
difference in LDL level.  
The impact of hypothyroidism on vascular and haemostatic risk 
factors for atherosclerosis has also been investigated in a few 
studies. Alterations in flow-mediated, endothelium dependent 
vasodilatation, which occurs early in atherogenesis, have been 
noted in patients with hypothyroidism. It is uncertain whether this 
is attributable to a direct effect of thyroid hormone deficiency or 
mediated through the hypercholesterolaemia induced by 
hypothyroidism[180]. Conflicting data exist regarding the effect of 
hypothyroidism on coagulation. Both increased[181] and 
decreased[182] platelet adhesiveness have been reported in 
hypothyroidism. The degree of hypothyroidism may determine its 
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ultimate effects on coagulation parameters[183]. In one study 
comparing moderate (TSH 10 to 50 mU/L) and severe 
hypothyroidism (>50 mU/L) with the euthyroid state, women 
with moderate hypothyroidism showed decreased fibrinolytic 
activity, with lower d-dimer levels, higher α2-antiplasmin activities, 
and higher levels of tissue plasminogen activator antigen and 
plasminogen activator inhibitor antigen. In contrast, those with 
severe hypothyroidism had higher d-dimer levels, lower α2-
antiplasmin activities, and lower tissue plasminogen activator 
antigen and plasminogen activator inhibitor antigen levels[183]. 
These results suggest a greater risk for thrombosis, which could 
precipitate myocardial infarction, in moderate hypothyroidism, and 
a bleeding tendency in severe hypothyroidism[142]. 
1.14.2.3. Haemodynamic changes associated with hypothyroidism 
The haemodynamic changes associated with hypothyroidism are 
opposite to those of hyperthyroidism, but they are accompanied 
by fewer symptoms and signs. The most common signs are 
bradycardia, mild hypertension, a narrowed pulse pressure, and 
attenuated activity on the precordial examination[105]. The two 
contributing factors to systemic hypertension in overt 
hypothyroidism are a marked increase in peripheral vascular 
resistance – which is the most widely recognised one, and the 
increase in arterial stiffness, which probably results from 
myxoedema of the arterial wall[184, 185]. In general, systemic 
hypertension associated with overt hypothyroidism is poorly 
controlled by conventional treatments, whereas it promptly 
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improves with achievement of euthyroidism[184]. These findings 
should encourage the routine assessment of thyroid function in all 
patients with pre-existing systemic hypertension that becomes 
resistant to pharmacological treatment[186]. Other characteristic 
but nonspecific findings are high serum concentrations of 
cholesterol and creatine kinase (the skeletal-muscle MM 
isoform)[105].  
The most-consistent cardiac abnormality recognized in patients 
with overt hypothyroidism is impairment of LV diastolic function, 
which is characterized by slowed myocardial relaxation and 
impaired early ventricular filling. LV systolic function usually is 
only marginally subnormal, as demonstrated by slightly reduced 
values of ejection fraction and stroke volume. The reduced cardiac 
preload, in combination with bradycardia and slight reduction in 
myocardial contractility, accounts for a less than normal cardiac 
output in overt hypothyroidism[187, 188]. Systemic vascular 
resistance may increase by as much as 50 percent[105]. The lower 
cardiac performance and the abnormalities in peripheral and 
proximal vascular function may contribute to the poor exercise 
tolerance in overt hypothyroidism [189]. However, because of the 
lowered demand for peripheral oxygen secondary to an overall 
lower metabolic rate and the resulting low cardiac output, heart 
failure is rare[105]. The lack of thyroid hormone effect on 
myocardial gene expression can be dramatic. Ladenson et al 
reported a substantially lower alpha-myosin heavy-chain mRNA 
level, a markedly elevated atrial natriuretic factor mRNA level and 
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decreased phospholamban mRNA level in an individual with 
profound hypothyroidism and dilated cardiomyopathy. The 
histological and clinical findings were reversible after 9 months of 
treatment with thyroxine, suggesting that alterations in gene 
expression in the dilated myopathic heart may be correctable when 
a treatable cause is identified[190]. Pericardial effusions and 
nonpitting oedema (myxoedema) can occur in patients with 
severe, long-standing hypothyroidism[105, 187, 190].  
Positron-emission tomographic studies of oxygen consumption in 
patients with hypothyroidism have revealed that myocardial work 
efficiency is lower than in normal subjects[191]. From 10 to 25 
percent of patients have diastolic hypertension, which, combined 
with the increase in vascular resistance, raises cardiac afterload and 
cardiac work[105, 191]. Although atrial arrhythmias are common 
and ventricular ectopy is rare in patients with hyperthyroidism, the 
opposite is true of hypothyroidism[113]. Hypothyroidism prolongs 
the cardiac action potential and the QT interval[192]. This, in turn, 
predisposes the patient to ventricular irritability and, in rare cases, 
acquired torsade de pointes[193]. These changes may arise at least 
in part from the regulatory effect of triiodothyronine on the 
expression of various ion channels in the heart[192]. Thyroxine 
therapy reverses all the cardiovascular changes associated with 
hypothyroidism[105]. Young patients with no evidence of organic 
heart disease can be given a replacement dose of thyroxine at the 
outset. Older patients, or those with known or suspected 
ischaemic heart disease, should initially be given about 25 percent 
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of the anticipated replacement dose, and the dose should then be 
increased in stepwise fashion at six-to-eight-week intervals[187]. In 
a large study of patients with hypothyroidism who were evaluated 
for clinical evidence of ischaemic heart disease after the initiation 
of thyroid hormone therapy, new or worsening angina or acute 
myocardial infarction was rare, and more patients had 
improvement in anginal symptoms[194]. These findings reinforce 
the important and potentially beneficial effects of thyroid 
hormone in improving the efficiency of myocardial oxygen 
consumption[191] and simultaneously lowering systemic vascular 
resistance[195, 196].  
1.14.2.4. Subclinical hypothyroidism 
Subclinical hypothyroidism (SCH), defined as a raised serum TSH 
level (>4.5 mU/L) with normal total or free T4 and T3 levels, is a 
commonly encountered condition in primary and secondary care 
with an overall prevalence of 4-10% in the general population and 
up to 20% in women above the age of 60[108]. SCH may 
represent an early stage of thyroid disease with an annual 
progression rate of 3-18% to overt hypothyroidism. Presence of 
antithyroid antibodies, serum TSH of more than 20 mU/L, a 
history of radioiodine ablation for Graves’ disease, a history of 
external radiation therapy for nonthyroid malignancies, a history 
of autoimmune diseases such as type 1 diabetes, and chronic 
lithium treatment are the strongest predictors of progression[108, 
197]. 
  76 
Patients with SCH are often asymptomatic; however, about 30% 
of patients may have symptoms suggestive of thyroid hormone 
deficiency including dry skin, poor memory, slow thinking, muscle 
weakness, fatigue, muscle cramps, cold intolerance, puffy eyes, 
constipation, and hoarseness. The Colorado Thyroid Disease 
Prevalence Study[10] showed that whilst euthyroid subjects 
experienced a mean 12.1% of all the above mentioned symptoms, 
patients with overt hypothyroidism had 16.6% and the ones with 
SCH reported an intermediate 13.7% of the symptoms.  
Some, but not all, cross-sectional studies have demonstrated that 
serum levels of total cholesterol and LDL cholesterol are higher in 
patients with SCH than in euthyroid controls. Danese et al[198] in 
their meta-analysis of the effect of therapy for subclinical 
hypothyroidism on serum lipid levels demonstrated a mean 
reduction in the total cholesterol level of 0.2 mmol/L and in the 
LDL cholesterol level of 0.26 mmol/L. 
Several neurobehavioral abnormalities such as depression, 
memory loss, cognitive impairment and a number of 
neuromuscular abnormalities have been shown to be associated 
with subclinical hypothyroidism; and there is evidence suggesting 
that SCH in pregnant women may impair the intellectual 
development of their euthyroid offspring. 
Whether SCH is an independent risk factor for cardiovascular 
disease is controversial. As mentioned earlier in this chapter, the 
findings of the original Whickham Survey[63] contradict those of 
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the Rotterdam Study[106] except for the common finding that 
thyroid autoimmunity was not associated with cardiovascular 
disease.  Cappola et al in their analysis of the Cardiovascular Health 
Study data found no relationship between subclinical 
hypothyroidism or overt hypothyroidism and prevalence or 
incidence of atherosclerotic disease, cardiovascular mortality, or 
all-cause mortality[132]. 
Controversy exists as to whether the general population should be 
screened for SCH or whether the condition routinely warrants 
thyroid hormone replacement. Villar et al in their recent systematic 
review found that based on current randomised clinical trials, 
thyroxine replacement therapy for subclinical hypothyroidism did 
not result in improved survival or decreased cardiovascular 
morbidity. Data on health-related quality of life and symptoms did 
not demonstrate significant differences between intervention 
groups. Some evidence indicated that thyroxine replacement 
improved some parameters of lipid profiles and left ventricular 
function[199]. Whilst most endocrinologists agree that patients 
with a TSH of higher than 10 mU/L, asymptomatic patients with 
positive antithyroid antibody, pregnant women and women who 
have ovulatory dysfunction and infertility should be considered for 
a therapeutic trial with thyroxine, routine treatment in patients 
with a TSH of 4.5-10 mU/L remains a grey area and best clinical 
practice continues to combine clinical judgment and patients’ 
preferences[82].  
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1.15. Thyroid and the phytoestrogens:  
Phytoestrogens are chemicals of plant origin that have the ability 
to cause oestrogenic and/or anti-oestrogenic effects. Lignans and 
isoflavones represent two of the main classes of phytoestrogens of 
current interest in clinical nutrition. Although ubiquitous in their 
occurrence in the plant kingdom, these bioactive nonnutrients are 
found in particularly high concentrations in flaxseeds (mainly a 
source of lignans such as enterolactone and enterodiol) and 
soybeans (mainly a source of isoflavons such as daidzein and 
genistein) and have been found to have a wide range of hormonal 
and nonhormonal activities[200].  
A number of studies have suggested that soybeans can be 
implicated in diet-induced goitre. Isoflavones have been shown to 
inactivate TPO in vitro. High-performance liquid chromatography 
(HPLC) fractionation and enzymatic assay of the soybean extract 
showed that the components responsible for inhibition of TPO-
catalyzed reactions coeluted with daidzein and genistein[201].  
Similar findings have been observed in vivo. Rats exposed to 
genistein for 20 weeks showed a dose dependent decrease in TPO 
activity, but their serum thyroid hormone level (T3, T4, TSH), 
thyroid weight and thyroid histopathology remained unchanged, 
suggesting that the remaining enzymatic activity of TPO was 
adequate to maintain thyroid homeostasis[202]. Additional factors 
appear necessary for soy to cause overt thyroid toxicity. These 
include iodine deficiency but may also include additional soy 
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components (most importantly, soy protein), other defects of 
hormone synthesis, or additional goitrogenic dietary factors[203, 
204]. Furthermore, if isoflavones do have adverse effects on 
thyroid function in susceptible individuals, there is no reason to 
think that isoflavone-containing soy foods would not have similar 
effects and in fact, a few studies have reported adverse effects of 
soy consumption on thyroid function in infants [205] and adults 
[206]. The effect of dietary soy phytoestrogens on thyroid function 
in patients with SCH is the subject of chapter 5 of this thesis. 
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C h a p t e r  2  
THE EFFECT OF SUBCLINICAL HYPOTHYROIDISM 
ON CARDIOVASCULAR OUTCOMES IN PATIENTS 
WITH TYPE 2 DIABETES MELLITUS 
2.1. Introduction: 
Type 2 diabetes mellitus (T2DM) is a complex metabolic disease 
characterized by increased peripheral insulin resistance and an 
insulin-secretory defect that varies in severity leading to raised 
blood glucose levels. T2DM constitutes about 85% to 95% of all 
diabetes cases in developed countries and accounts for an even 
higher percentage in developing countries. In 2007, it was 
estimated that there were 246 million people with diabetes in the 
adult population in the seven regions of International Diabetes 
Federation (IDF). In 2003, the total was 194 million. It is now a 
common and serious global health problem, which for most 
countries has evolved in association with rapid cultural and social 
changes, ageing populations, increasing urbanisation, dietary 
changes, reduced physical activity and other unhealthy lifestyle and 
behavioural patterns. The incidence of T2DM is expected to 
double over the next 20 years. Based on the latest Quality and 
Outcomes Framework (QoF) data (2006), the estimated national 
prevalence of diabetes is 3.55% in the United Kingdom. 
Circulatory disorders associated with diabetes include coronary 
heart disease (CHD), stroke, peripheral arterial disease, 
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cardiomyopathy, and congestive heart failure. Several clinical trials 
have shown that diabetes generally results in early death from 
cardiovascular diseases (CVDs). The impact of cardiovascular 
disease was compared in non-diabetics and diabetics in the 
Framingham cohort. In the first 20 years of the study about 6% of 
the women and 8% of the men were diagnosed as diabetics. The 
incidence of cardiovascular disease among diabetic men was twice 
that of non-diabetic men. Among diabetic women the incidence of 
cardiovascular disease was three times that of non-diabetic 
women[207]. Multiple Risk Factor Intervention Study (MRFIT) 
also showed that absolute risk of CVD death was three times 
higher for diabetic than nondiabetic men of every age group, 
ethnic background, and risk factor level, after adjustment for age, 
race, income, serum cholesterol level, systolic blood pressure (BP), 
and reported number of cigarettes per day[208]. The results of the 
OASIS (Organisation to Assess Strategies for Ischaemic 
Syndromes) registry later established that diabetic patients with no 
previous cardiovascular disease have the same long-term 
morbidity and mortality as nondiabetic patients with established 
cardiovascular disease after hospitalisation for unstable coronary 
artery disease[209]. 
Subclinical hypothyroidism (SCH), defined as a raised serum TSH 
level with normal total or free T4 and T3 levels, has been associated 
with a greater prevalence of aortic atherosclerosis and  myocardial 
infarction, in some but not in all studies[63, 106, 132] (cf. 1.14.2.4). 
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SCH is relatively common in patients with type 2 diabetes with a 
prevalence of 6.8% [210].  
We hypothesised that if SCH contributed to an increase in 
cardiovascular risk then, intuitively, its effect would be exaggerated 
in patients with type 2 diabetes – a high cardiovascular risk 
population. Therefore, we conducted a retrospective analysis of 
cardiovascular outcomes comparing patients with type 2 diabetes 
with SCH and without SCH, using the Hull and East Yorkshire 
diabetes database. 
2.2. Subjects & Methods:  
Patients were identified from an electronic diabetes database of 
15760 diabetes patients at Hull Royal Infirmary from 1993 to June 
2005. An initial search of 6540 consecutive patients entered on the 
register up to the end of 2000, a cut off to ensure capture of 
clinical outcomes at least five years after the initial diagnosis of 
SCH. A total of 542 patients with a raised TSH (>5 mU/L) and a 
normal free T4 were identified. All of the case notes were reviewed 
and laboratory values/clinical findings were ascertained by the 
author. Patients with type 1 diabetes, progression to overt 
hypothyroidism, current thyroxine therapy, those on antithyroid 
treatment or history of antithyroid treatment, those with a history 
of or current treatment with lithium and those with a single TSH 
measurement were excluded.  A total of 394 patients with type 2 
diabetes and untreated SCH were identified that composed the 
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case group. To identify the control group, a TSH range of 0.5-3.0 
mU/L (normal lab range: 0.5-4.7mU/L) was used as the database 
search criteria.  The reason for setting 3.0 mU/L as the upper cut 
off TSH value is the controversy over the upper normal limit of 
TSH, as some authors have suggested that the current upper limit 
of the population reference range is skewed by the inclusion of 
persons with occult thyroid dysfunction[70, 71] (cf. 1.9.3). 
Acknowledging that the concept of a narrower TSH normal range 
is yet to be widely accepted[74], the researchers felt that 3.0 mU/L 
would provide a safe margin to ensure exclusion of people with 
subclinical hypothyroidism in the control group. An initial search 
of the database identified over 800 patients with TSH 
measurements in the range of 0.5-3.0 mU/L. After excluding 
those with type 1 diabetes, previous or current thyroid dysfunction 
on treatment with thyroxine or antithyroid drugs, those with a 
history of or current treatment with lithium and those with a single 
TSH measurement, there were 472 patients in the control group. 
The 394 case group patients were compared with these 472 type 2 
diabetes patients with a TSH of 0.5-3.0 mU/L (normal lab range: 
0.5-4.7mU/L) during the same period of time.  TSH, free T4, free 
T3, HbA1c, lipid profile, presence of coronary heart disease, 
peripheral vascular disease, cerebrovascular and cardiovascular 
events and smoking history were recorded from the review of the 
notes. Based on one previous study [106] our sample size was 
powered to detect a difference in odds of 1.90 (80% power, 5% 
significance).   
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The relationship between SCH and cardiovascular mortality was 
assessed by logistic regression from which odds ratios (ORs) and 
95% confidence intervals (CIs) were calculated[211, 212]. Three 
models were constructed: 1. unadjusted odds ratios; 2. adjusted for 
age and sex; 3. further adjustment for smoking status (yes/no), 
body mass index (BMI) (weight [Kg]/height2 [m]), diastolic blood 
pressure (mmHg), systolic blood pressure (mmHg), HbA1c (%) 
and lipids (mmol/L).  An arbitrary level of 5% statistical 
significance was assumed (two-tailed).  P values were calculated by 
the likelihood ratio method.  GLIM4 statistical computer package 
was used to analyze the data. 
2.3. Results:  
There were 394 patients with type 2 diabetes having SCH (a 
prevalence of 6%) and 472 patients with type 2 diabetes without 
SCH.  The baseline demographic parameters of both groups are 
given in Table 2.3.1. Table 2.3.2 shows the prevalence of CVD in 
the case and the control groups. The incidences of new 
cardiovascular events are depicted in Table 2.3.3. Mortality from 
CVD and other causes in the two groups is summarised in Table 
2.3.4. 
The mean age of patients with SCH was 73.1 years compared to 
71.1 years in patients without SCH.  There were more females in 
patients with SCH (83.7%) compared to patients without SCH 
(18%).  The mean duration from diagnosis of SCH to baseline of 
the study was 7.9 years. There were 222 new cardiovascular events 
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(28.1 person years) in patients with Type 2 Diabetes having SCH 
compared to 246 cardiovascular events (31.1 person years) in 
patients without SCH.    There was no relationship between 
baseline or follow up serum TSH levels and cardiovascular 
mortality.  The unadjusted odds ratio (OR) was 1.27(95%CI=0.86, 
1.87, p =0.26).  Adjusting for age and sex did not alter the nature 
of this relationship: OR=1.17(95%CI=0.88, 1.56, p=0.27), and 
neither did further adjustment for the other baseline covariates: 
OR=1.15 (95% CI= 0.58, 2.27, p=0.68).  The unadjusted OR for 
all cause mortality was 1.83 (95%CI=1.36, 2.46, p value <0.001). 
Table 2.3.1: The baseline demographic parameters of the case and control 
groups; values given as mean ± SEM (Range) 
Parameters Cases (n=394) Controls (n=472) 
Age in years 73.1 ± 0.57 (28 - 98) 71.1 ± 0.57 (34-96) 
Sex (m/f) 148/246  387/85 
Smokers % (n) 11.93 (47) 16.95 (80) 
BMI in kg/m2 30.1 ± 0.40 (18.8-45.2) 29.5 ± 0.33 (17.4-46.4) 
TSH in mU/L 8.1 ± 0.01 (5.1 - 9.9) 1.1 ± 0.02 (0.30 - 4.10)
Systolic BP in mmHg 149 ± 1.4 (93 - 217) 148 ± 1.4 (80 - 212) 
Diastolic BP in mmHg 80 ± 0.8 (42 - 90) 82 ± 0.79 (40 - 92) 
Total Cholesterol in 
mmol/L 
5.7 ± 0.1 (3.4 - 6.9) 5.5 ± 0.1 (3.2 - 6.8) 
HbA1c in % 8.2 ± 0.1 (5.8 - 9.3) 8.1 ± 0.1 (5.6 - 9.2) 
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Table 2.3.2: Prevalence of CVD in the case and control groups 
CVD Cases (n=394) Controls (n=472) 
Coronary artery disease 88 (22.3%) 103 (21.8%) 
Cerebrovascular events 12 (3.0%) 12(2.5%) 
Peripheral vascular disease 22 (5.6%) 27 (5.7%) 
Coronary artery disease 
and cerebrovascular 
events 
10 (2.5%) 14 (3.0%) 
Coronary artery disease 
and peripheral vascular 
disease 
20 (5.1%) 21 (4.5%) 
 
Table 2.3.3: New cardiovascular events in the two groups 
New CVD Cases (n=394) Controls (n=472) 
Coronary artery disease 95(55.9%) 105(56.8%) 
Cerebrovascular events 40(23.5%) 56 (30.3%) 
Peripheral vascular disease 34 (20%) 23 (12.4%) 
Ischemic colon 1(0.6%) 1(0.5%) 
Total 170 185 
 
Table 2.3.4: Mortality from CVD and other causes in the two groups 
Mortality Cases (n=394) Controls (n=472) 
Coronary artery disease 44 (11.2%) 45 (9.5%) 
Cerebrovascular events 5 (1.3%) 27 (5.7%) 
Other causes 47 (11.9%) 103 (21.8%) 
Total 96 (24.4%) 175 (37.1%) 
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2.4. Discussion: 
In this study there was no increase in cardiovascular mortality in 
patients with type 2 diabetes and SCH compared to patients with 
type 2 diabetes without SCH. There was no relationship between 
serum TSH levels and cardiovascular mortality in this cohort of 
patients with type 2 diabetes.  The prevalence of SCH in this 
population was found to be 6.0% that is not dissimilar to that of 
6.8% reported[210]. Sixty percent of patients with SCH were 
females compared to 18% of patients without SCH.  This 
corresponds to the literature where the highest age-and sex-
specific rates are in women older than 60 years .  There were more 
smokers in the control group (17%) than patients with SCH 
(12%).  In spite of adjusting for these variables, there was no 
increase in cardiovascular disease in patients with SCH and type 2 
diabetes.   
These data are in accord with the 20-year follow-up of the 
Whickham cohort, where the rates of death from all causes or 
from cardiovascular causes were not significantly higher in 
subjects who had SCH at baseline than in those with euthyroidism 
at base line[63] and also in line with the results of the 
Cardiovascular Health Study[132] which did not show an 
association between SCH and cardiovascular mortality or events.  
These results are the converse to the Rotterdam Study that found 
SCH as a strong indicator of risk for atherosclerosis and 
myocardial infarction[106] in a comparably aged population to this 
study, though they found a higher SCH prevalence of 11.8%.   
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Patients with type 2 diabetes have much higher risk of two to 
fourfold of both coronary heart disease and stroke and increased 
case-fatality rates[208].  It is reassuring that these data suggest that 
SCH does not contribute to the excess risk of cardiovascular 
mortality in patients with type 2 diabetes, at least 5 years after its 
diagnosis. 
In conclusion, the findings of this study do not support the 
routine use of thyroxine in type 2 diabetic patients with SCH if the 
aim of the treatment is to minimise their long-term CV risk. 
However, in the presence of symptoms that can be attributed to 
hypothyroidism, a trial treatment with thyroxine, based on clinical 
judgment and patient’s preferences, may be warranted.  
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C h a p t e r  3  
THE EFFECT OF THYROID DYSFUNCTION ON N-
TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE 
CONCENTRATIONS 
3.1. Introduction:  
 
Measurement of Brain Natriuretic Peptide (BNP) used in 
conjunction with other clinical information is useful in establishing 
or excluding the diagnosis of congestive heart failure in patients 
with acute dyspnoea[213]. BNP is a prognostically robust tool for 
risk stratification across the spectrum of acute coronary 
syndromes  and it can reliably predict the presence or absence of 
left ventricular dysfunction on echocardiogram[214]. In the largest 
study involving  3177 Framingham probands,  BNP showed 
excellent negative predictive values for excluding severe systolic 
LV dysfunction, but because positive predictive values were weak, 
it indicated  that BNP was unsuitable for screening in the 
community or high risk population[215]. The decrease of 
Natriuretic Peptides (NPs) following treatment of heart failure has 
been shown to correlate with clinical benefit, improvement of 
functional parameters such as ejection fraction and surrogate 
parameters of therapy success such as renin levels and a decrease 
in heart rate[216, 217]. 
A change in BNP levels may be associated with other conditions. 
Pulmonary disease resulting in right ventricular dysfunction leads 
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to increased BNP values[218]. Kruger et al found a good 
correlation of BNP with right ventricular dysfunction but not with 
clinical outcome in 50 patients with pulmonary embolism[219]. 
Other non-cardiac causes associated with elevated NPs are renal 
failure, ascitic cirrhosis, hyperaldosteronism, hypercortisolism, 
subarachnoid haemorrhage, COPD, carcinoma of lung,  increasing 
age,  gender (higher in women and in the elderly)[220], and lower 
body mass indices[221]. 
Although the exact mechanisms of BNP release are still unclear, 
its release seems to be stimulated by increased left ventricular (LV) 
wall stress and volume expansion[222]. BNP is synthesized as a 
pro-hormone and is secreted by proteolytic cleavage. Finally, the 
biologically active part BNP and the larger aminoterminal part N-
Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) are 
released in equimolar amounts in circulation[220]. The in-vivo half 
life of BNP is 20 minutes and shorter than that of NT-proBNP, 
which is about 2 hours[223], and absolute values of BNP are 
significantly lower than values of NT-pro-BNP despite equimolar 
secretion. NT-proBNP was also found to be the only independent 
predictor of disease for the New York Heart Association (NYHA) 
class I and NYHA class II and therefore may be a more discerning 
marker for the detection and evaluation of heart failure than 
BNP[224]. 
The actual function of BNP is thought to be cardioprotective 
through increasing natriuresis and diuresis, vasodilatation and 
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directly inhibiting the sympathetic nervous system and the renin–
angiotensin system[225]. Changes to these parameters have also 
been found in patients with thyroid dysfunction. Triiodothyronine 
decreases systemic vascular resistance by dilating the resistance 
arterioles of the peripheral circulation[195]. As a result of the 
decrease in systemic vascular resistance, the effective arterial filling 
volume falls, causing an increase in renin release and activation of 
the angiotensin-aldosterone axis[226]. This, in turn, stimulates 
renal sodium reabsorption, leading to an increase in plasma 
volume. Thyroid hormone also stimulates erythropoietin secretion. 
The combined action of these two is an increase in blood volume 
and preload, which further increases cardiac output[105]  We have 
already shown that changes in thyroid function are associated with 
alteration in the concentration of Cystatin C through a possible 
metabolic rate mediated mechanism[227]; this study has assessed 
whether similar changes are reflected with NT-proBNP 
concentrations following treatment of hypo and hyperthyroidism. 
Schultz et al have shown alterations of NT-proBNP levels across a 
range of thyroid dysfunctions[228]. Our study assessed whether 
the previously observed alterations in NT-proBNP levels with 
thyroid dysfunction are consistent and tries to interpret the results 
in the light of more recently published data on biological variation 
of this analyte. 
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3.2. Subjects and Methods: 
To see a significant difference in the NT-proBNP levels between 
baseline hyperthyroid and hypothyroid groups (80% power and a 
significance level of 5%) a sample size of 10 per group was 
calculated using nQuery Advisor (version 4, Statistics Solutions). 
Seventeen patients (12 female, 5 male, median age 51yrs, range 24-
77) with newly diagnosed biochemical hypothyroidism (Thyroid 
Stimulating Hormone (TSH)>5.0mU/L (reference interval 0.5-
4.7mU/L) and free Thyroxine (fT4)<9pmol/L (9-24)) and  21 
patients (16 female, 5 male, median 48yrs, range 21-66) with newly 
diagnosed hyperthyroidism (TSH<0.05mU/L, fT4>24pmol/L 
and free triiodothyronine (fT3)>5.3pmol/L (0.5-5.3)) had NT-
proBNP measured at baseline and when they subsequently 
became euthyroid (TSH<4.8pmol/L, fT4 9-24pmol/L). Patients 
were sequentially recruited from the Endocrine out-patient clinic 
at Michael White Centre, Hull Royal Infirmary over a three month 
period. The enrolled patients did not have a history of coronary 
heart disease. Using Boston Criteria[229] heart failure was clinically 
excluded in all participants at the initial and follow-up visit(s). 
Hypothyroid patients were treated with thyroxine 100µg for 6 
weeks. The 4 patients who were not rendered euthyroid on this 
regime became so when given 150µg thyroxine for a further 6 
weeks. Twelve of the hyperthyroid patients became euthyroid after 
receiving carbimazole 20mg for 6 weeks. Five became hypothyroid 
at this stage so had 100µg thyroxine added and were euthyroid by 
week 12 on the combination. Two patients required an increase in 
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their carbimazole dose to 40mg after 6 weeks and became 
euthyroid by week 18. All samples taken, spun immediately and 
serum frozen at -20ºC, until batch analysed in a single run at the 
end of the study. The study gained local Ethics Committee 
approval and patients gave their written informed consent for 
participation. 
All thyroid assays were performed on an Abbott Architect i4000 
immunoassay analyser (Abbott Diagnostics Division, Maidenhead, 
Berkshire, UK). The NT-proBNP measurements were done using 
Biomedica NT-proBNP assay; this assay has a detection limit of 5 
pmol/L at 95% B/Bo and an intra-assay CV of less than 4% at 
666 pmol/L. The following values for NT-proBNP were provided 
by the kit manufacturer: <250 pmol/L: negative result; 250-350 
pmol/L: borderline result; >350 pmol/L: positive result. Serum 
creatinine was measured on a Beckman LX20 instrument 
(Beckman Coulter UK Ltd, High Wycombe, UK). 
3.3. Results: 
Kolmogorov-Smirnov test, histograms and normal plots showed 
that the distribution of data (NT-proBNP values) in both hyper 
and hypothyroid groups were non-Gaussian; this was also 
confirmed by Shapiro-Wilk test (using GB-STAT version 9.0, 
Dynamic Microsystems, Inc). Therefore non-parametric methods 
were used to analyse the NT-proBNP data. SPSS for Windows 
(version 12, SPSS Inc) was used for statistical analysis unless 
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otherwise specified. Mann-Whitney test was employed to compare 
the NT-proBNP levels in the hypothyroid group versus the 
hyperthyroid group before and after treatment to euthyroidism; 
the test did not show any statistically significant difference 
between NT-proBNP levels in the two groups either before 
(p=0.706) or after treatment (p=0.179).Using Wilcoxon Signed-
Ranks test, the changes in NT-proBNP were compared before 
and after treatment in each of the two groups of patients. This 
showed a statistically significant rise in the NT-proBNP 
concentrations in the hypothyroid group following treatment 
(p<0.001) (Figure 3.1). The subjects weights in the hypothyroid 
group did not significantly change after treatment to euthyroidism 
(mean weight in kg±SD before and after treatment: 74.84±9.08 vs 
74.14±9.05; p=0.417). There was a marginally significant overall 
fall in the NT-proBNP levels in the hyperthyroid group of patients 
after they achieved euthyroidism (p=0.05) (Figure 3.2). However, 
there was a significant weight gain in this group of patients 
following treatment to euthyroidism (mean weight in kg±SD 
before and after treatment 72.27±18.13 vs 74.78±17.24; p<0.05). 
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Figure 3.1: Changes in NT-proBNP with hypothyroidism (excluding the 
patient where NT-proBNP increased from 1211 to 1236 pmol/L from the 
graph; all values are included in the statistical analysis) 
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Figure 3.2:  Changes in NT-proBNP with hyperthyroidism (excluding the 
patient where NT-proBNP fell from 584 to 429 pmol/L from the graph; all 
values are included in the statistical analysis) 
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3.4. Discussion: 
The presented data shows that hypothyroidism reversibly alters 
NT-proBNP concentrations. Positron-emission tomographic 
studies of oxygen consumption in patients with hypothyroidism 
have revealed that myocardial work efficiency is lower than in 
normal subjects[191]. Also, with an increase in systemic vascular 
resistance and slowed diastolic relaxation and filling[196], a high 
incidence of heart failure in patients with hypothyroidism may be 
expected. However, it seems that other haemodynamic changes 
associated with hypothyroidism i.e. a reduction of blood volume 
and a decrease in renin release, can offset these effects and in 
practice heart failure is rare because the cardiac output is usually 
sufficient to meet the lowered demand for peripheral oxygen 
delivery[190]. It therefore seems more likely that the changes in 
NT-proBNP in this group are as a result of a metabolic rate 
mediated effect on peptide production, as has been suggested 
previously with cystatin C[227]. 
Whilst cardiac failure is certainly recognized in hyperthyroidism, in 
practice it is uncommon other than in the occasional patient with 
severe, longstanding hyperthyroidism who develops hyperthyroid 
cardiomyopathy or the so-called rate-related heart failure[112] This 
may well help explain the baseline similarities between the hyper- 
and hypothyroid group. Also, given the known relationship 
between higher BMI and lower natriuretic concentrations[221, 
230], it is surprising that the weight gain found in this group after 
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treatment did not lead to a larger change in NT-proBNP 
concentrations than was found in the hypothyroid patients. 
In an assessment of NT-proBNP biological variability, Wu et al 
suggest that a change of 90% for NT-proBNP is necessary before 
results of serially collected data can be considered statistically 
different[231] and week-to-week intraindividual biological 
variation of NT-proBNP is estimated to be 30% in patients with 
stable heart failure[232].  Although this study supports the changes 
in NT-proBNP with hypothyroidism as demonstrated earlier by 
Schultz et al[228], in the context of the biovariability of this 
natriuretic peptide the magnitude of the observed changes 
presented here are unlikely to be as clinically relevant. In contrast 
to Schultz et al, who found 4 fold higher levels of NT-proBNP in 
hyperthyroid subjects compared to the ones with hypothyroidism, 
we did not observe a significant difference between the baseline 
levels of NT-proBNP in the two groups. Apart from using 
different assays in the two studies (Roche Elecsys NT-proBNP in 
Schultz et al study versus Biomedica NT-proBNP used in this 
study), a number of factors may account for the different results 
obtained in the two studies. Schultz et al assumed normal 
distribution of NT-proBNP values based on normal plots and 
histograms that are useful visual tools to test for normality. 
However, adding Kolmogorov-Smirnov or Shapiro-Wilk tests to 
these can give a more accurate assessment of the data distribution. 
At least two other studies i.e. PRIDE study and Mueller et al study 
that used the same Roche assay with larger number of samples 
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(204 and 180 respectively) found that NT-proBNP data were non-
Gausian[230, 233]. The assumption of normality has significant 
implications on the statistical power and the results. Other 
distinguishing factors between the two studies that could be 
potential sources of bias are: 
• Use of carbimazole as the sole antithyroid agent in 
hyperthyroid group in this study versus use of 
mercaptoimidazole and/or radio-iodine in Schultz et al 
study. 
• Schultz at al study is a dominantly female study with only 1 
male subject; the male female ratio in the present study is 
1:4, and more reflective of the overall sex distribution of 
thyroid disease in the general population 
• 15 years age difference between the mean age in hyper and 
hypothyroid groups in Schultz et al study compared to 3 
years mean age difference in the present study. 
In conclusion, this study has shown that treating hypothyroidism 
to euthyroid state is associated with a rise in NT-proBNP 
concentrations and the treating hyperthyroidism leads to a fall. 
These changes seem to be secondary to a metabolic rate mediated 
effect on peptide production. However, in comparison to the high 
biological variation of NT-proBNP, the magnitude of these 
changes is likely to be of limited clinical relevance.   
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C h a p t e r  4  
THE EFFECT OF THYROID DYSFUNCTION ON 
PLASMA PEPTIDE YY AND GHRELIN 
4.1. Introduction: 
Hyper and hypothyroidism are typically associated with weight 
loss and weight gain respectively. Whilst these changes in weight 
have classically been attributed to changes in energy expenditure 
and metabolic demand associated with thyroid dysfunction, it is 
not clear whether thyroid hormones have an additional effect on 
gut hormones PYY and ghrelin that may further contribute to 
changes in weight. Obesity is an important and well known 
independent risk factor for cardiovascular morbidity and 
mortality[234-236], and the possible intermediary role of PYY and 
ghrelin in weight changes associated with thyroid dysfunction is 
the subject of this chapter. 
PYY belongs to a peptide family known as the PP-fold peptides – 
pancreatic polypeptide (PP), and neuropeptide Y (NPY) are other 
members of this family. Their common tertiary structure, 
consisting of an α-helix and polyproline helix connected by a β-
turn, results in a characteristic U-shaped peptide known as a PP-
fold. In addition to a shared tertiary structure, there is significant 
homology between peptide sequences within the family. They all 
have 36 amino acids and contain several tyrosine residues. 
Furthermore, their biological activity is dependent on C-terminal 
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amidation[237]. PYY is present in two forms, PYY1–36 and PYY3–
36. PYY3–36, the major circulating form[238], is a truncated 34-
amino acid form created by cleavage of the N terminus Tyr-Pro 
residues by dipeptidyl peptidase IV (DPPIV) [239]. DPPIV is 
found in two forms; as a transmembrane protein widely expressed 
on endothelial, epithelial, and lymphoid tissue and as a circulating 
form in plasma. It is responsible for dipeptide cleavage from many 
peptides including hormones, neuropeptides, and chemokines 
[240]. However, the actions of DPPIV in regulating the relative 
postprandial concentrations of PYY1–36 and PYY3–36 are unknown 
(Cf Chapter 6)[237]. 
PYY is secreted from the entire gastrointestinal tract but 
particularly from the distal portion. PYY immunoreactive cells are 
almost absent in the stomach, sparse in the duodenum and 
jejunum, common in the ileum and colon, and at very high levels 
in the rectum. Food intake results in release of PYY from these 
cells. The PYY level rises to a plateau at 1–2 h post ingestion, with 
these peak levels influenced by both the number of calories and 
the composition of the food consumed. Higher plasma 
concentrations are seen after isocaloric meals of fat, compared 
with intake of protein or carbohydrate. It has been shown in 
healthy humans that gastric distension does not affect PYY 
secretion[241], however, other stimuli, such as gastric acid, 
cholecystokinin, and luminal bile salts, also stimulate PYY 
release[242],. The onset of this release occurs even before 
nutrients have reached the distal parts of the gastrointestinal tract 
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where PYY is produced. This infers peptide release may occur via 
a neural reflex, possibly through the vagus nerve. Other factors 
also alter circulating PYY. Plasma PYY concentrations are 
increased by IGF-1, bombesin, and calcitonin-gene-related 
peptide, and they are reduced by glucagon-like peptide 1 (GLP-
1)[237]. 
PYY has long been known to exert numerous effects on the 
gastrointestinal tract. Administration of PYY increases the 
absorption of fluids and electrolytes from the ileum after a meal 
and delays pancreatic and gastric secretions, gallbladder emptying, 
and gastric emptying. PYY, when administered peripherally, also 
affects other systems in the body, e.g. it results in a reduction in 
cardiac output, accompanied by vasoconstriction. PYY causes a 
reduction in glomerular filtration rate, a reduction in plasma renin 
and aldosterone activity, and a decrease in lipolysis secondary to a 
direct effect on adipose tissue[237]. The truncated form, PYY3–36 
has been reported to have potent effects on appetite. In man, 
PYY3–36, given iv at physiological levels, to normal-weight human 
volunteers, reduces calorie intake by over 30% [243]. Furthermore, 
the duration of food intake and their subjective feelings of hunger 
decrease, without an alteration in gastric emptying. This effect 
persists 2 h after the infusion is terminated, despite the 
concentration of circulating PYY3–36 returning to basal levels. 
Plasma PYY is suppressed in patients with morbid obesity. 
However, the anorectic effect is preserved in obese subjects, with 
calorific intake reduced to the same extent as lean subjects[244]. 
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This suggests that administration of PYY3–36 could perhaps be an 
effective therapy for obesity. Indeed, chronic peripheral 
administration to rodents results in a depressed food intake 
throughout the study, and body weight is reduced in comparison 
with controls [243]. 
The central actions of PYY, in contrast to peripheral PYY, are 
orexigenic. PYY injections into the third, lateral, or fourth cerebral 
ventricles [245], paraventricular nucleus, or hippocampus potently 
stimulate food intake in rodents [246]. The truncated form, PYY3–
36, also simulates food intake when administered 
intracerebroventricularly. This effect is reduced in both Y1_/_ mice 
and Y5_/_ mice [247]. Therefore, although PYY3–36 does not have a 
high affinity for these receptors, they may mediate its central 
feeding effect. 
Ghrelin is the first identified peripherally active orexigenic factor. 
It is a 28-amino acid peptide with an acyl side chain, n-octanoic 
acid, which has been found to be essential for its actions on 
appetite. Ghrelin is the endogenous agonist of the GH 
secretagogue receptor (GHS-R)[248].  
The oxyntic cells of the stomach are the main site of ghrelin 
production. About two thirds of circulating ghrelin is thought to 
be produced by the stomach. However, ghrelin-producing cells 
have also been found in the duodenum, ileum, caecum, and colon. 
Both circulating and nutritional factors from within the gut lumen 
may trigger these cells to release ghrelin. It is, however, thought to 
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be calorie intake, which is the primary regulator of plasma ghrelin 
levels [249]. Circulating ghrelin concentrations have been shown to 
rise during a period of fasting, peak (to double the baseline 
concentration) just before eating, and fall rapidly after a meal, 
suggesting a role as a meal initiator [250]. However, recent work 
has failed to show a relationship between plasma ghrelin 
concentrations and meal initiation [251]. Furthermore, plasma 
ghrelin peaks can be conditioned by altering feeding schedule, 
suggesting a possible role in physiological preparation for a meal, 
rather than initiation of feeding [252]. Plasma ghrelin 
concentrations also show a diurnal variation, in phase with leptin, 
with highest levels in the morning and lowest at night [250].  
GHS-Rs are widely expressed. In the central nervous system 
(CNS), they are found in the pituitary and hypothalamus, whereas 
peripheral receptor expression has been described in the 
myocardium, stomach, small intestine, pancreas, colon, adipose 
tissue, liver, kidney, placenta, and T cells. In addition, there is some 
evidence of additional receptor subtype(s) that bind the 
nonoctanoylated form of ghrelin.  
Ghrelin has been demonstrated to be a short-term regulator of 
food intake in both animals and man. Both central and peripheral 
ghrelin administrations increase calorie intake in animals [253]. 
Furthermore, infusing antighrelin antibodies into the rat brain 
inhibits fasting-induced feeding, supporting ghrelin’s role as an 
endogenous regulator of food intake [254]. Ghrelin is also effective 
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in man, producing a 28% increase in food intake, when given iv to 
normal weight volunteers [255].  
Ghrelin may also be a regulator of long-term energy balance. 
Plasma ghrelin levels are strongly correlated with body weight. 
There is a reversible suppression of ghrelin associated with obesity, 
such that ghrelin levels normalize after diet-induced weight loss. 
The fall in plasma ghrelin concentration after bariatric surgery for 
obesity is thought to be partly responsible for the suppression of 
appetite and weight loss seen after these operations [256]. Seven-
day administration of ghrelin to rodents stimulates weight gain and 
adiposity secondary to increased food intake [249, 253]. This fat 
deposition is promoted by a change in metabolism from fatty acid 
oxidation to glycolysis [249]. However, ghrelin null animals do not 
have significantly altered body weight or food intake when 
compared with wild-type littermates [257].  
In addition to its actions on food intake, ghrelin induces a dose-
dependent stimulation of GH release from the pituitary via its 
actions on the GHS-R in the hypothalamus [248, 249]. However, it 
is important to note that the effects of ghrelin on food intake are 
independent of its effects on GH. Whereas ghrelin is known to 
increase adiposity, GH reduces adiposity. The effect of chronic 
ghrelin administration on food intake and body weight is still 
effective in dwarf GH-deficient rats[249]. 
Ghrelin may be the first of a number of orexigenic factors that 
have physiological activity in man. However, as yet, no other 
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circulating hormone derived from the gastrointestinal tract has 
been shown to stimulate food intake[237].  
We have previously demonstrated that changes in thyroid function 
are associated with alterations in the concentration of low 
molecular weight peptides cystatin-C and N-Terminal Pro-B Type 
Natriuretic Peptide through a metabolic rate mediated 
mechanism[227, 258]. This study has assessed whether changes in 
thyroid status are associated with changes in plasma PYY and 
ghrelin concentrations. 
4.2. Subjects and Methods: 
Seventeen patients (12 female, 5 male, median age 51yrs, range 24-
77) with newly diagnosed biochemical hypothyroidism [Thyroid 
Stimulating Hormone (TSH) > 5.0 mU/L (normal range 0.5-4.7 
mU/L)] and free thyroxine (fT4) ≤ 0.70 ng/dl [mean ± SD: 0.46 ± 
0.21; normal range 0.70-1.86 ng/dl (9-24 pmol/L)] and  21 
patients (16 female, 5 male, median 48yrs, range 21-66) with newly 
diagnosed hyperthyroidism (TSH < 0.05 mU/L, fT4 > 1.86 ng/dl 
(mean ± SD: 3.10 ± 1.38) and free triiodothyronine (fT3) > 0.34 
ng/dl [mean ± SD: 1.10 ± 0.77; normal range: 0.03-0.34 ng/dl 
(0.5-5.3 pmol/L )] had fasting plasma PYY and ghrelin measured 
at baseline and when they subsequently became euthyroid (TSH < 
4.8 mU/L, fT4 0.70-1.86 ng/dl). Patients were sequentially 
recruited from the endocrine out-patient clinic at Michael White 
Centre, Hull Royal Infirmary over a three month period. 
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Hypothyroid patients were treated with thyroxine 100µg once 
daily (od) for 6 weeks. The 4 patients who were not rendered 
euthyroid on this regime became so when given 150µg thyroxine 
od for a further 6 weeks. Twelve of the hyperthyroid patients 
became euthyroid after receiving carbimazole 20mg od for 6 
weeks. Five became hypothyroid at this stage so had 100µg 
thyroxine od added and were euthyroid by week 12 on the 
combination. Two patients required an increase in their 
carbimazole dose to 40mg daily after 6 weeks and became 
euthyroid by week 18. All samples taken, spun immediately and 
serum frozen at -20ºC, until batch analysed in a single run at the 
end of the study. The study gained local ethics committee 
approval and patients gave their written informed consent for 
participation. 
All thyroid assays were performed on an Abbott Architect i4000 
immunoassay analyser (Abbott Diagnostics Division, Maidenhead, 
Berkshire, UK). Plasma ghrelin-like and PYY-like 
immunoreactivity were measured using specific and sensitive 
radioimmunoassays as previously described[259, 260]. All samples 
were assayed simultaneously and in duplicate to eliminate the 
effect of inter-assay variation. The ghrelin assay cross-reacted fully 
(100 %) with both acylated and des-acylated ghrelin and did not 
cross-react with any other known gastrointestinal or pancreatic 
hormone. The antiserum, SC-10368 (Santa Cruz Biotechnology, 
California, USA), was used at a final dilution of 1:50,000. 125I 
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ghrelin was prepared using Bolton & Hunter reagent (Amersham 
International UK) and purified by high pressure liquid 
chromatography. The assay detected changes of 25 pmol/L with a 
95 % confidence limit. The intra-assay coefficient of variation was 
5.5 %. 
The PYY assay cross-reacted fully with PYY1–36 and PYY3–36 and 
did not cross-react with pancreatic polypeptide, neuropeptide Y, 
or any other known gastrointestinal hormone. The antiserum 
(Y21) was raised in a rabbit against synthetic porcine PYY 
(Bachem, UK) coupled to bovine serum albumin by 
glutaraldehyde and was used at a final dilution of 1:50 000. 125I 
PYY was prepared by the iodogen method and purified by high 
pressure liquid chromatography. The assay detected changes of 2 
pmol/L with a 95 % confidence limit. The intra-assay coefficient 
of variation was 5.8 %. 
4.3. Results: 
Shapiro-Wilk test, normal plots and histograms (using GB-STAT 
version 9.0, Dynamic Microsystems, Inc), showed that data 
distribution for PYY in both groups, and ghrelin in hypothyroid 
subjects were normal and that data were non-Gaussian for ghrelin 
in hyperthyroid subjects. Therefore Wilcoxon Signed-Ranks test 
was used to compare ghrelin levels in hyperthyroid patients before 
and after treatment and parametric methods were used to analyze 
the rest of the data. SPSS for Windows (version 12, SPSS Inc) was 
used for statistical analysis unless otherwise specified.  
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There was no significant change in PYY levels in either group 
before and after treatment (mean PYY in pmol/L±SD before and 
after treatment: 24.81±12.10 vs. 23.22±15.27, p=0.428 
hypothyroid; 19.47±8.09 vs. 20.87±10.26, p=0.464 hyperthyroid). 
The observed changes in ghrelin in both groups did not reach 
statistical significance either (mean ghrelin in pmol/L±SD before 
and after treatment: 761.32±435.46 vs. 697.60±376.09, p=0.227 
hypothyroid; p=0.058 for hyperthyroid group with 6 negative 
ranks, 15 positive ranks and a trend towards higher ghrelin levels 
after treatment). The subjects’ weights in the hypothyroid group 
did not change significantly after treatment to euthyroidism (mean 
weight in kg ± SD before and after treatment: 74.84 ± 9.08 vs. 
74.14 ± 9.05; p=0.417). There was a significant weight gain in the 
hyperthyroid group of patients following treatment to 
euthyroidism (mean weight in kg ± SD before and after treatment 
72.27 ± 18.13 vs. 74.78 ± 17.24; p<0.05). 
 
4.4. Discussion: 
The presented data shows that change in thyroid status does not 
significantly alter gut hormones PYY and ghrelin levels.  
Gut hormones have an important physiological role in 
postprandial satiety. The gut contains a diffuse population of 
endocrine cells that release several circulating hormones in 
response to changes in luminal nutriment content. Recent 
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evidence has shown that gut hormones administered at 
physiological concentrations can influence appetite in rodent 
models and humans. Ghrelin is a strong stimulant for food intake 
and growth hormone secretion. Plasma ghrelin levels are inversely 
correlated with body weight and rise following weight loss in 
humans. Though calorie intake appears to be the primary regulator 
of plasma ghrelin levels, the exact mechanisms mediating ghrelin 
release are unknown. PYY is an anorectic hormone which is 
released from the gastrointestinal L-cells post-prandially. Food 
intake and body weight are reduced in rodents chronically treated 
with peripheral PYY3–36.[261] 
The hypothalamus is a center for interpretation and integration of 
adiposity related long-term humoral signals mediated by insulin 
and leptin as well as short-term situational and meal related signals 
from various sources including the gastrointestinal tract, the 
environment and higher brain centers.[262] Excess food intake, 
characteristic of hyperthyroidism, is thought to be a compensatory 
mechanism in response to the higher energy demand associated 
with this condition. However, Kong et al have demonstrated in 
animal studies that triiodothyronine directly stimulates feeding at 
the level of hypothalamus via ventromedial nucleous and its 
numerous projections to other areas of the hypothalamus[263], 
and this direct effect may account for the observed weight gain in 
5-10% of patients with thyrotoxicosis. 
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In conclusion, thyroid dysfunction does not alter plasma PYY and 
ghrelin concentrations and changes in weight associated with 
thyroid dysfunction are more likely to be due to a combination of 
altered metabolic rate and the direct effect of T3 or lack of it on 
hypothalamus. 
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C h a p t e r  5  
THE EFFECT OF DIETARY SOY PHYTOESTROGENS 
ON THYROID FUNCTION AND INSULIN RESISTANCE 
IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM: 
A DOUBLE BLIND CROSSOVER STUDY 
5.1. Introduction: 
As discussed earlier, Subclinical hypothyroidism is a common 
condition with a prevalence of 4 to 10% in the general 
population[9, 10, 108]. Studies have suggested that it may lead to 
an increase in cardiovascular risk through a number of possible 
mechanisms including a rise in insulin resistance[264].  
It has been shown that naturally occurring phytoestrogens can 
reduce insulin resistance and have beneficial effects on other 
cardiovascular risk factors in postmenopausal women and in 
patients with type 2 diabetes[265, 266]. In view of substantial 
evidence that soy protein intake improves serum lipid profiles, the 
US Food and Drug Administration and the American Heart 
Association issued a recommendation of daily consumption of 
≥25 g soy protein as a preventive measure to reduce the risk of 
heart disease[267]. However, the effect and safety of soy 
phytoestrogens on the thyroid is not well established[201].  
Nevertheless, the effect of soy phytoestrogens in patients whose 
thyroid function is already compromised may be more clinically 
important, particularly in pregnancy where the prevalence of 
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subclinical hypothyroidism is around 2 to 5%[10, 268] , and has 
been associated with a reduced intelligence quotient in the 
offspring of the affected patient[269].   
This double blind, cross over trial was undertaken to determine 
the effect of soy phytoestrogens on thyroid function and 
cardiovascular risk markers in patients with subclinical 
hypothyroidism. We compared the effect of combining 30g of soy 
protein with either 2mg phytoestrogens or 16mg of 
phytoestrogens (the latter being the amount expected in a 
vegetarian diet with high phytoestrogen intake, or in a health food 
supplementation) with the aim of providing definitive evidence on 
the activity, safety and/or possible benefits of phytoestrogens in 
patients with compromised thyroid function. 
5.2. Subjects and Methods:  
Patients with subclinical hypothyroidism with a TSH value of 
between 5-15 mU/L (normal range 0.5-4.7 mU/L) with a normal 
fT4 were recruited following identification through routine 
biochemical testing performed at Hull Royal Infirmary between 
July 2005 and August 2006.  The baseline characteristics are given 
in Table 5.1.   
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Table 5.1: Baseline characteristics 
Characteristics 2mg followed by 
16mg phytoestrogen 
group 
16mg followed by 
2mg phytoestrogen 
group 
Number of patients  30 30 
TPO antibody positive  
n (%) 
20 (66.7) 18 (60) 
Male/Female 4/26 6/24 
Age (Mean ± SD) 56.7 ± 18.0 58.7 ± 13.1 
Weight kg 76.4 ± 19.1 80.9 ± 20.1 
BMI kg/m2 28.3 ± 6.4 29.0 ± 7.2 
 
Exclusion criteria included patients taking thyroxine or drugs that 
could interfere with thyroid function such as lithium, carbimazole 
and propylthiouracil, patients whose dose of antihypertensive or 
lipid lowering medications had been modified within 3 months of 
their participation in the trial, and antibiotic use within the last 3 
months prior to enrolment in the study, as antibiotics are known 
to change gut microflora and thus would interfere with 
phytoestrogen metabolism[270].  At randomisation and during 
each visit, all subjects were instructed to maintain their diet and 
level of physical activity throughout the study.  In addition, 
subjects were required to avoid alcohol, herbal, vitamin or mineral 
supplementation.  Compliance checks and dietary reinforcement 
were performed at each visit.  One 24 hour urine collection was 
made during the study period to measure urine iodine excretion 
and to exclude iodine deficiency. 
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A randomized, double-blind, cross over design was employed.  In 
view of the known palatability issue encountered previously with 
the soy protein powder[271], patients were given a 2 week run in 
and if they were not able to tolerate the 2mg or 16mg preparation 
then they were withdrawn from the study.  Patients were replaced 
until the 60 patients needed to give adequate statistical power to 
the study were recruited. A total of 11 patients in the 2 mg arm 
and 12 patients in the 16mg arm were unable to tolerate the soy 
preparation within the initial 2 week period and therefore did not 
proceed to enter the main study. Sixty patients found the 
preparation tolerable; a total of 30 patients initiated with the 2mg 
preparation and 30 patients on the 16mg preparation. After an 8 
week wash out period, the participants crossed over to the 
alternative treatment for 8 weeks (second phase). Each box 
contained the number of sachets required for eight weeks of 
treatment plus 6 sachets marked as reserve.  A computer generated 
randomisation list was used. All subjects gave their written 
informed consent and the protocol was approved by the Hull and 
East Riding local research ethics committee. The study was 
registered as ‘a double-blind, placebo-controlled, crossover trial of 
soy phytoestrogens in patients with compensated hypothyroidism’ 
on UK Clinical Trials Gateway website (http://www.controlled-
trials.com/ukctg) with International Standard Randomised 
Controlled Trial Number (ISRCTN) of 55827330. 
From a previous study with a significant reduction in T4 , a sample 
size of 50 patients in a cross over design was calculated giving 
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80% power to detect a mean decrease of 0.4 nmol/L of T4, with a 
two sided alpha error of 0.05. 
At the beginning and end of each phase, following an overnight 
fast, weight and blood pressure were measured and blood samples 
were collected.  The blood pressure was measured after the 
patients were seated quietly for at least 5 minutes in a chair and the 
right arm supported at heart level.  A cuff bladder encircling at 
least 80% of the arm was used to ensure accuracy.  Blood pressure 
measurements were performed using an automated device (NPB-
3900; Nellcor Puritan Bennett, Pleasanton, CA) during each study 
visits.  Two readings were obtained at the beginning of each visit 
at least one minute apart.  If there was more than a 5 mmHg 
difference in systolic BP between the 2 readings, a third reading 
was obtained.  Fasting venous blood samples were collected into 
serum gel, EDTA, and fluoride oxalated tubes, separated by 
centrifugation at 2000g for 15 min at 4oC, and the aliquots stored 
at -80oC within 1 hour of collection.  Plasma glucose was 
measured using a Synchron LX20 analyzer (Beckman-Coulter), 
and serum insulin was assayed using a competitive 
chemiluminescent immunoassay performed using the DPC 
Immulite 2000 analyzer (Euro/DPC, Llanberis, U.K.). The 
coefficient of variation of this method was 8%, calculated using 
duplicate study samples.  The analytical sensitivity was 2µU/ml 
and there was no stated cross-reactivity with proinsulin. The 
insulin resistance was calculated using the Homeostasis Model 
Assessment method (HOMA-IR = (Insulin x glucose)/22.5)[272] .  
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Urinary iodine measurements in 24 hour urine collections were 
undertaken by ICP-MS to monitor for iodine repletion and plasma 
phytoestrogen measurement was undertaken by LC-MS/MS 
(Central Science Laboratory, Sand Hutton, York, UK). 
The low dose phytoestrogen preparation consisted of 30 g of soy 
protein concentrate (70% proteins) containing 2 mg of 
phytoestrogens, whereas high dose phytoestrogen preparation 
contained 16 mg of phytoestrogens.  The phytoestrogen material 
(Solgen 40) was supplied by Solbar Ltd, Israel, and prepared by 
Essential Nutrition, Ltd, Brough, UK, who also randomised the 
sachets.   
5.3. Results: 
Paired t tests were used to compare thyroid function tests before 
and after treatment with 2mg and 16mg phytoestrogens, whereas 
Wilcoxon signed-ranks test was applied to phytoestrogen data that 
violated the assumptions of normality when tested using the 
Kolmogorov-Smirnov test.  The period and the carryover effect 
that may have occurred from the cross-over design were also 
tested using the appropriate Student t test.  Independent samples t 
test was used to compare plasma phytoestrogen levels after wash 
out and after 2 mg/16 mg phytoestrogens.    Statistical analysis 
was performed using SPSS for Windows NT version 14.0 (SPSS, 
Chicago, IL).  An arbitrary level of 5% statistical significance (two-
tailed) was assumed.   
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Of the 60 patients randomized, 10 patients withdrew in the first 
arm and 6 patients in the second phase (loose stools: 3, 
progression to symptomatic hypothyroidism: 6, transient 
thyroiditis: 4, use of antibiotics: 1 , worsening of diabetes control: 
1, moved out of area: 1).  Six patients completing both arms of the 
study were excluded due to plasma phytoestrogen values greater 
than 3 SD above the mean suggesting consumption of additional 
phytoestrogens.  Intention to treat analysis was done.  A flow 
chart describing the progress of the patients in the study is given 
in figure 5.1 as per the CONSORT (Consolidated Standards of 
Reporting Trials) statement[273]. 
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Patients with
subclinical
hypothyroidism
identified
Soy protein 30g/day +
Phytoestrogens 2 mg/day
x 8 weeks
(n=26)
(Withdrawals = 4 for second arm)
Soy protein 30g/day +
Phytoestrogens 16mg/day x 8
weeks.
(n= 30)
(Withdrawals = 4)
Randomisation
Excluded due to
erratic
phytoestrogen
values (n=4)
Soy protein 30g/day +
Phytoestrogens 2 mg/day
x 8 weeks.(n=30)Withdrawals
= 6)
Soy protein 30g/day +
Phytoestrogens 16mg/day x 8
weeks
(n=24)
(Withdrawals = 2 for second arm)
Excluded due to
erratic
phytoestrogen
values (n=2)
Washout
8 weeks
 
 
 
 
Figure 5.1 
Total number of patients who 
completed both phases = 44, 
Total number of patients for 
analysis = 38
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There was a significant reduction in systolic blood pressure of 
(mean ± SD) 2.57 ± 3.9 mmHg and diastolic blood pressure of 
(mean ± SD) 1.64 ± 3.7 mmHg after 16 mg phytoestrogen phase 
(Table 5.2).  There was also a significant reduction of systolic 
blood pressure of (mean ± SD) 1.1 ± 3.9 mmHg after 2mg 
phytoestrogen phase but no significant reduction in diastolic 
blood pressure.  There were no changes in the lipid profile and 
hsCRP pre and post treatment (Table 5.3). 
Table 5.2: Weight and blood pressure of patients after 16mg phase and after 
2 mg phase by paired t test 
 
 
16mg phytoestrogen phase
(95% CI)(p value) 
2mg phytoestrogen phase 
(95% CI)(p value) 
Weight (kg) 79.45 ± 20.45 vs. 79.29 ± 
20.50 
(0.18 – 0.50) (0.939) 
78.35 ± 19.41 vs. 78.36 ± 19.10  
(-0.30 – 0.53) (0.585) 
Systolic BP 
(mmHg)  
140.71 ± 7.7 vs. 138.14 ± 8.5 
(1.51 – 3.64) (<0.001) 
140.75 ± 8.2 vs. 139.64 ± 7.8 
(0.05 – 2.2) (0.04) 
Diastolic BP 
(mmHg) 
76.76 ± 6.7 vs. 76.00 ± 5.6  
(1.62 – 3.74) (0.002) 
76.77 ± 6.9 vs. 77.38 ± 6.2 
(-1.67 – 0.44) (0.245) 
 
 
There was a significant improvement in insulin resistance 
measured by HOMA-IR (mean ± SD) [5.11 ± 12.2 vs. 4.2 ± 9.9 
(p value= 0.02) 95% CI 0.12, 1.63] and plasma glucose (mean ± 
SD) [5.6 ± 1.1 vs. 5.3 ± 1.2 (p value= 0.006) 95% CI 0.11, 0.59] 
after 16mg phytoestrogen phase but not after 2mg phytoestrogen 
phase (table 5.4).   
 
 
 
  120 
Table 5.3: Lipid Profile and hsCRP of patients post 16mg phase and post 2 
mg phase by paired t test 
Tests* Mean ± SD Sig. (2 
tailed) 
Total Cholesterol post 16mg vs.  post 
2mg phytoestrogen (mmol/L) 
5.50 ± 1.15 vs. 5.71 ± 1.34 0.12 
HDL Cholesterol post 16mg vs.  
post 2mg phytoestrogen (mmol/L) 
1.37 ± 0.32 vs. 1.40 ± 0.34 0.22 
LDL Cholesterol post 16mg vs.  post 
2mg phytoestrogen (mmol/L) 
3.49 ± 1.10 vs. 3.70 ± 1.25 0.17 
Total Cholesterol/HDL ratio post 
16mg vs. post 2mg phytoestrogen 
4.13 ± 0.99 vs. 4.21 ± 1.03 0.47 
Triglycerides post 16mg vs.  post 
2mg phytoestrogen (mmol/L) 
1.34 ± 0.67 vs. 1.34 ± 0.64 0.83 
Hs-CRP post 16mg vs. post 2mg 
phytoestrogen (mg/L) 
3.85 ± 3.32 vs. 3.72 ± 3.38 0.70 
 
Table 5.4: Insulin resistance of patients before and after phytoestrogens 
 Mean ± SEM Sig.(
2taile
d) 
Insulin pre and post 16mg 
phytoestrogen phase (µIU/mL) 
17.30 ± 5.8 vs. 15.25 ± 4.6 0.09 
Insulin pre and post 2mg 
phytoestrogen phase (µIU/mL) 
12.54 ± 1.4 vs. 11.14 ± 1.2 0.20 
Glucose pre and post 16mg 
phytoestrogen phase (mmol/L) 
5.64 ± 0.2 vs. 5.30 ± 0.2 0.006 
Glucose pre and post 2mg 
phytoestrogen phase  
(mmol/L) 
5.33 ± 0.2 vs. 5.42 ± 0.2 0.19 
HOMA-IR pre and post 16mg 
phytoestrogen phase 
5.11 ± 1.9 vs. 4.28 ± 1.5 0.02 
HOMA-IR pre and post 2mg 
phytoestrogen phase 
3.14 ± 0.5 vs. 2.97 ± 0.5 0.48 
 
Thyroid function tests after 2mg and 16mg phytoestrogen 
treatments are given in table 5.5.  The fT3 values were significantly 
higher after treatment with 2mg phytoestrogen (mean ± SD) (4.07 
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± 0.67 vs. 4.39 ± 0.63 pmol/L p <0.01) but there were no 
changes in other thyroid parameters after treatment.  Subgroup 
analysis revealed that fT3 values were significantly higher after  2 
mg phytoestrogen phase (4.11 ± 0.62 vs. 4.56 ± 0.65 p value 
<0.01) but not after 16mg phytoestrogen phase (4.22 ± 0.71 vs. 
4.25 ± 0.61 p value=0.80) in patients who received 16 mg 
phytoestrogen in phase 1.  There were no significant differences in 
thyroid function tests in patients entering the 2 mg phytoestrogen 
in phase 1.  Thyroid antibody titres did not alter before or after 
either treatment. 
Table 5.5: Thyroid function tests before and after phytoestrogens 
Thyroid Function Tests 
fT3 in pmol/L, fT4 in pmol/L 
and TSH in mU/L 
Mean ± SD Sig. 
2 
tailed 
Mean % 
change 
fT3 pre and post 16mg 
phytoestrogen phase 
4.22 ± 0.71 vs. 4.25 ± 
0.61  
0.80 2% 
fT3 pre and post 2mg 
phytoestrogen phase 
4.07 ± 0.67 vs. 4.39 ± 
0.63 
<0.01 11% 
fT4 pre and post 16mg 
phytoestrogen phase 
11.74 ± 1.68 vs. 11.9 ± 
1.57 
0.43 2% 
fT4 pre and post 2mg 
phytoestrogen phase 
11.61 ± 1.47 vs. 11.87 ± 
1.40 
0.20 3% 
TSH pre and post 16mg 
phytoestrogen phase 
6.26 ± 2.18 vs. 6.31 ± 
2.44 
0.84 2% 
TSH pre and post 2mg 
phytoestrogen phase 
6.40 ± 1.79 vs. 6.07 ± 
2.03 
0.36 -1% 
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The plasma extracts were screened for the presence of sixteen 
different phytoestrogens.  The lignan profile, including 
enterolactone and enterodiol, was constant but low throughout 
the study. The levels of non-soy phytoestrogens such as 
formononetin, biochanin A and coumestrol were also low and 
static. The baseline values were consistent with the standard 
United Kingdom low content soy diet.  The plasma phytoestrogen 
levels attained after 2 mg phytoestrogens (mean ± SD) ((daidzein 
(9.5 ± 10.2 ng/ml vs. 4.6 ± 5.5 ng/ml p  = 0.06) (genistein (10.9 ± 
16.0 ng/ml vs. 8.2 ± 10.3 ng/ml p = 0.52)) and 16mg 
phytoestrogens (mean ± SD) ((daidzein (20.2 ± 21.5 ng/ml vs. 
24.8 ± 28.5 ng/ml p = 0.56) (genistein(35.6 ± 39.2 ng/ml vs. 51.5 
± 63.6 ng/ml p =  0.33)) were comparable in both groups.  The 
baseline levels of phytoestrogens were comparable to the levels 
after the washout phase (mean ± SD) (daidzein 2.6 ± 2.9 ng/ml 
vs. 2.9 ± 2.7 ng/ml p = 0.82) (genistein 2.6 ± 3.7ng/ml vs. 3.5 ± 
5.3ng/ml) which confirmed that after outliers were excluded, the 
remaining patients had both adhered  to the protocol and avoided 
extra dietary sources of phytoestrogens.   
The 24 hour urine iodine estimation revealed urinary iodine 
excretion of 206 ± 105 microgram/day (mean ± SD) (range: 106 - 
672 microgram/day).     
 5.4. Discussion: 
This study showed that there was a significant reduction of blood 
pressure and insulin resistance after 16mg phytoestrogen 
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preparation and a significant reduction of diastolic blood pressure 
after 2mg phytoestrogen phase as well as no clinical effect on 
thyroid function even in patients with subclinical hypothyroidism.  
Although the magnitude of reduction in blood pressure in our 
study is small, the public health implications may be important, 
given that a small reduction in population wide blood pressure can 
lead to a substantial decrease in cardiovascular risk in the society.  
Historically, epidemiologic observations of diet and cardiovascular 
disease in Japan and China have linked soy-product consumption 
with a reduced cardiovascular risk[271, 274] .  Studies of 
phytoestrogen intakes in Western countries, indicate average daily 
intakes around 2 mg phytoestrogens[275, 276] equivalent to the 
low dose phytoestrogen preparation used here. Higher 
phytoestrogen levels are found in United Kingdom 
vegetarians[277] , with levels corresponding to the 16mg 
phytoestrogen phase of this study, which was consumed in 
addition to a Western diet avoiding soy products.  The 
hypotensive effect of soy phytoestrogens is reported though the 
literature is conflicting[278-280].  These studies are difficult to 
compare as different soy phytoestrogen/placebo/comparator 
preparations have been used in different study populations. To 
attempt to see if this was a real effect, we added soy 
phytoestrogens to soy protein and then compared two different 
phytoestrogen doses. We intentionally chose patients with 
subclinical hypothyroidism who are reported to have a higher 
cardiovascular risk[106] and probably a more sensitive thyroid 
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gland to external insult, and therefore a greater chance to see if 
changes were to take place. Whilst the 16mg of phytoestrogen was 
more effective than 2 mg at reducing blood pressure, it could be a 
matrix effect with the soy protein. In another study with high dose 
phytoestrogens alone (132mg daily) without soy protein we found 
that there was no effect on cardiovascular disease markers in 
patients with type 2 diabetes[281].   
There was unexpectedly no significant improvement in lipid 
profile with neither high nor low dose phytoestrogens in this 
study.  On the other hand, when 132mg of phytoestrogens with 30 
g soy protein was used, cardiovascular parameters were reduced 
within the same time frame in patients with type 2 diabetes[266].  
The lack of improvement of lipid profile in this study might be 
due to the lower dose of phytoestrogens used.  However, 
supplementation with phytoestrogens alone (40–150 mg/day) 
have not altered lipid profiles[282, 283].    Conversely, isolated soy 
protein has been shown to improve lipid profile[284]. Beneficial 
effects have also been observed with different combinations of 
soy protein and phytoestrogens concentrations[266, 280, 285, 
286].   
Overall there was no significant difference in any of the thyroid 
parameters after 2mg or 16mg soy phytoestrogen 
supplementation. However, subgroup analysis showed that 
patients who received the low dose, 2 mg phytoestrogens, after the 
high dose (16 mg phytoestrogens) phase had an increase in the fT3 
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levels although the T4 or TSH values did not differ.  The 
magnitude of the rise of fT3 in this group is unlikely to be of 
clinical significance and this was not seen in the 2mg 
phytoestrogen phase leading to the 16mg phase.  In a similar study 
that we have performed in patients with type 2 diabetes there was 
an increase in the T4 levels by 8.4% but  T3 levels were unchanged 
by 132mg of phytoestrogens in soy protein[266]. There is evidence 
to show synergism of soy phytoestrogens with iodine deficiency in 
producing hypothyroid effects in rats[287].  A urinary iodine 
concentration of 100 microgram/L corresponds to an intake of 
about 150 microgram per day, which is the daily requirement of 
iodine in adults[288].  In our study, all patients had sufficient 
iodine excretion of more than 100microgram per day.  It has been 
shown that soy phytoestrogens inactivate thyroid peroxidase both 
in vitro and in vivo[289] , in this study there was no alteration in 
thyroid peroxidase antibody status in patients with subclinical 
hypothyroidism. That there was no clinically significant change in 
thyroid parameters is reassuring, especially in view of the 
observation that children of women with high serum TSH 
concentrations during pregnancy performed less well on tests of 
neuropsychological development[290].   
The 16mg phytoestrogen used in this study is the amount 
expected in a vegetarian diet with high phytoestrogen intake, or 
health food supplementation.  This study shows that with respect 
to thyroid function, 16 mg of phytoestrogen is safe and there is no 
need to alter dietary advice to this subgroup of the population 
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with regard to soy consumption. However, dietary intake of 
phytoestrogens in Asian diets has been estimated to be in the 
range of 30-50 mg per day of combined phytoestrogen aglycone 
equivalents[291, 292] and the effect of this dose on compromised 
thyroid function remains unclear.  
There was a significant improvement in insulin resistance after the 
16mg phytoestrogen phase indicating the activity of the 
preparation. This is in accord with reports of diets containing soy 
protein rich in phytoestrogens that improve insulin resistance in 
ovariectomised cynomolgus monkeys[293],  and other studies 
showing reduced insulin levels in patients with type 2 diabetes  as 
well as in postmenopausal women[266, 285]. This is particularly 
relevant in view of studies suggesting increase in cardiovascular 
mortality in patients with subclinical hypothyroidism[264].  In a 
cross-sectional cohort study TSH was significantly associated with 
insulin resistance in euthyroid range after adjustment for age and 
sex[294].  However, it is important to note that we found no effect 
on insulin resistance when using phytoestrogen alone with no soy 
protein, whereas this study has shown an effect of high dose 
phytoestrogen with soy protein, but not low dose phytoestrogen 
with soy protein. This would suggest that soy protein on its own 
(like phytoestrogen) would not be affective, but rather it is the 
combination with phytoestrogen that is important.  The reduction 
of insulin resistance in patients with subclinical hypothyroidism 
should in theory have a protective effect on their cardiovascular 
risk profile.   
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In conclusion, the cardiovascular protection suggested for 
phytoestrogens epidemiologically may be through their positive 
effect on insulin resistance and blood pressure.  However low and 
high levels of dietary phytoestrogens have no clinical effect on 
thyroid function even in patients compromised with subclinical 
hypothyroidism.   
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C h a p t e r  6  
GENERAL DISCUSSION  
 
This thesis examines the relationship between thyroid dysfunction 
and the cardiovascular risk by combining a retrospective 
cardiovascular outcome study (chapter 2) with 3 clinical trials that 
employ surrogate cardiovascular risk markers (chapters 3 to 5). By 
combining the findings of these studies with the review of 
literature that has been provided in the Introduction (Chapter 1) 
and the ‘discussion’ sections of individual studies, the author 
concludes that the effects of thyroid dysfunction on the 
cardiovascular system are subtle, and these effects do not always 
translate into adverse cardiovascular outcomes.  
As noted in the introduction to this thesis, considerable amount of 
evidence points to various effects of excess thyroid hormone or 
the lack of it on the cardiovascular system. However, the exact 
mechanisms through which these effects are exerted are not 
wholly understood. There also remain unsolved clinical dilemmas. 
The debate on the treatment of SCH for example, has been 
ongoing for years, and despite published consensus statements on 
the subject, there does not seem to be unanimity among the 
experts as to when to treat SCH [82, 83]. Today, the controversy 
goes beyond the experts and extends itself to patients, patient 
advocacy groups and politicians[295]. 
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The first study presented in this thesis, ‘Chapter 2: the effect of 
subclinical hypothyroidism on cardiovascular outcomes in patients 
with type 2 diabetes mellitus’, is an attempt to see whether SCH 
incurs additional risk of CVD in patients with type 2 diabetes. The 
study is genuine in that this relationship had never been studied in 
T2DM population before. This study did not show an increase in 
cardiovascular events or mortality as a result of SCH in the study 
population. The main limitation of the study is a marked 
difference in sex distribution of patients in the case versus the 
control group (83.7% females in the cases vs. 18% females in the 
controls). This disparity was imposed on the researchers by the 
limited number of control patients extracted from the database 
after limiting the upper cut off point of TSH value to 3.0 mU/L 
for the reason explained before (cf. 1.9.3), and after implementing 
the rest of the exclusion criteria as detailed in section 2.2. This 
limitation is at least partly accounted for by statistically adjusting 
for the sex distribution difference. Although female predominance 
in the case group might as well provided a protective effect against 
CVD, their 2 years higher mean age has no doubt attenuated this 
protective effect to some extent.  
One should also consider the generic limitations of retrospective 
studies in establishing causal relationships compared to 
prospective randomised controlled clinical trials. However, given 
the nature of SCH, prospective studies are likely to be confounded 
by progression to overt hypothyroidism during the course of the 
study, and that the magnitude of change and response to 
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treatment would likely to be small and difficult to distinguish from 
controls[296]. 
All the same, the study is novel in terms of its target population 
and its findings are in line with 2 major studies on the subject, i.e., 
the Whickham Survey[63] and the Cardiovascular Health 
Study[132]; as well as recent Cochrane review[199], and a smaller 
study that did not find an association between SCH and presence 
or severity of cardiovascular disease[297].  
The lack of significant effect from SCH on cardiovascular 
outcomes (Chapter 2) is in a way reflected in the results of the 
second study (Chapter 3, ‘The effect of thyroid dysfunction on N-
terminal pro-B-type natriuretic peptide concentrations’), which 
shows that NT-proBNP – a marker of heart failure – is not 
significantly affected by thyroid dysfunction. Compared to a 
previous publication by Schultz et al[228] on the subject, here we 
adopted a new approach in interpreting the findings in the context 
of the wide biological variation of NT-proBNP (cf. 3.4.). Along 
the way, Schultz et al paper was also critically examined and we 
explained the reason why our findings differ from those of Schultz 
et al [228] (cf. 3.4.). 
There is a body of evidence pointing to a negative correlation 
between levels of circulating thyroid hormones and IL-6[174, 175, 
298]. Although this relationship has been well studied in non-
thyroidal illness, the evidence on such relationship with 
hypothyroidism is lacking. Given the association of IL-6 with low 
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levels of thyroid hormones, and the recent findings indicating the 
importance of IL-6 as an independent predictor of CHF[176], one 
might assume that hypothyroidism and CHF may have a mutually 
deteriorating effect on each other. This hypothesis has yet to be 
tested in clinical trials and may be of interest for future research. 
Chapter 4 assesses the plasma levels of gut hormones PYY and 
ghrelin in relation to hyper and hypothyroidism, exploring the 
possibility of a role for these gut hormones in the weight changes 
associated with thyroid dysfunction. Similar to the case of NT-
proBNP, we did not found a change in plasma PYY and ghrelin 
levels.  
The role of gut hormones PYY and ghrelin in regulating food 
intake and therefore weight is well established. Abdominal obesity 
is a major component of the metabolic syndrome and is 
incorporated in both the National Cholesterol Education 
Program’s Adult Treatment Panel (ATP) III definition and the 
International Diabetes Federation (IDF) criteria along with 
dyslipidaemia, hypertension, and glucose intolerance[299, 300]. It 
has been shown that disrupting ghrelin signalling by targeting the 
ghrelin or ghrelin receptor genes blunts weight gain from a high-
fat diet in mice[301, 302]. Also, simultaneous deletion of ghrelin 
and its receptor (double knock-out mice) enhances the metabolic 
phenotype of single gene-deficient mice compared with wild-type 
mice, possibly suggesting the existence of additional molecular 
components of the endogenous ghrelin system[303]. The double 
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knock-out mice in this study showed decreased body weight, 
increased energy expenditure, and increased motor activity on a 
standard chow diet[303]. Therefore, inhibiting ghrelin can serve as 
a therapeutic means for weight reduction and provides ample food 
for future research. One recent try along this line is the 
identification and characterisation of human GOAT (ghrelin O-
acyl transferase), the lipid transferase that modifies the O-linked 
octanoyl side group of ghrelin molecule[304]. This modification is 
crucial for ghrelin's physiological effects including regulation of 
feeding, adiposity, and insulin secretion. Because octanoylated 
ghrelin promotes food intake and adiposity and also suppresses 
insulin secretion and impairs glucose tolerance, GOAT may 
provide a critical molecular target in developing novel therapeutics 
for obesity and type 2 diabetes[304]. 
Another anorexigenic gut hormone, which may at least partly exert 
its effect on appetite and weight through suppression of 
circulating ghrelin levels, is oxyntomodulin[305]. Subcutanously 
self-administered oxyntomodulin in healthy overweight and obese 
volunteers resulted in weight loss and a change in the levels of 
adipose hormones consistent with a loss of adipose tissue[306]. 
The anorectic effect of oxyntomodulin was maintained over the 
course of the trial (4 weeks)[306] and can potentially be used in the 
treatment of obesity and the metabolic syndrome.  
PYY is a high affinity substrate for dipeptidyl peptidae IV (DPP-
IV)[307]. Whereas cleavage of glucagons-like peptide-1 (GLP-1) 
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by DPP-IV causes inactivation, cleavage of PYY yields the active 
form, PYY3–36. Thus, DPP-IV does not inactivate PYY but, rather, 
alters its biological activity. Given the role of obesity in type 2 
diabetes, prevention of the formation of such an endogenous food 
intake inhibitor by a DPP-IV inhibitor may be undesirable. 
Although the results of clinical trials on DPP-IV inhibitors 
indicating that they are weight neutral[308] argues against this,  
with rising popularity of DPP-IV inhibitors as promising anti-
diabetic agents, the relationship between PYY and DPP-IV 
warrants further experimentation. 
The recurring theme of Chapters 2-4 was also seen in Chapter 5, 
where we found that a daily supply of phytoestrogens and 30 g of 
soy protein improved 2 components of the metabolic syndrome, 
i.e. insulin resistance and blood pressure, without affecting the 
thyroid function tests. It was interesting to see that these 
reductions in insulin resistance and blood pressure were 
independent of body weight. However, longer term prospective 
trials are needed to see whether the improvement seen in these 2 
markers of the metabolic syndrome actually translate into better 
cardiovascular outcomes. 
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